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1. ,1752’8&7,21$1’6800$5<
This study provides an overview of the background to, and focuses on, some of the major issues
arising from the marketing and sale of pharmaceuticals1 on-line.  The study is not intended to
provide a complete summary of the current pharmaceutical regulatory regime in the EU, nor
to provide an exhaustive description of obstacles to the introduction of electronic commerce
in the pharmaceutical sector.
It starts by providing a brief background to the current debate and by setting out the present position
in the EU pharmaceutical sector.  It then examines some of the barriers which currently
inhibit the exploitation of electronic commerce in the sector - in particular, the restrictions on
electronic commerce across national borders (including cross-border delivery) caused by
barriers to parallel imports and other practical and regulatory issues relating to cross-border
purchases (including pricing systems).
The study includes seven Annexes providing more detailed background to the pharmacists’ monopoly,
price controls and reimbursement, the EU regulatory framework for pharmaceuticals, the
regulation of advertising and promotion of pharmaceutical products and jurisdiction over
intellectual property (",3") disputes.  Another Annex summarises answers to a questionnaire
sent out to around 180 market players in the EU and elsewhere seeking their views on current
issues in the pharmaceutical market.  Each Annex briefly considers the situation in the EU,
while also covering distinctive local variations in the UK, France, Italy, Germany and
Belgium and, to a limited extent, the situation in the US and other non-EU countries.
The volume of electronic commerce is increasing at an exponential rate, and there is no reason to
believe that the pharmaceutical sector will remain unaffected.  Patients will seek to obtain
better health care delivered more efficiently; EU Member States want the same but it must be
delivered at a reduced cost. Both will use electronic commerce if it provides these benefits.
National boundaries and regulatory barriers will not necessarily be a deterrent.  As a result,
EU Member States have a choice: either they can react to electronic commerce developments
in the pharmaceutical sector (and probably therefore not meet their citizens’ expectations); or
they can facilitate them, by allowing the development of new services which add value, while
establishing new safeguards that will continue to protect the consumer and ensure national
health care standards.
By way of conclusion, we propose the following tentative recommendations:
(a) In considering the adoption of any policy on the impact of electronic commerce on
the European pharmaceutical sector, the Commission should recognise:-
(i) the global nature of the Internet;
(ii) the importance of public funding and the health insurance industry;
(iii) the drive by producers and wholesalers for continuing cost reduction in
pharmaceutical distribution;
1
 Medicinal products are referred to in this study as either ‘pharmaceutical products’ or as ‘pharmaceuticals’.
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(iv) the opportunities to benefit the retail distribution chain as a whole from doctor
through pharmacist to patient .
(b) The Commission should review the regulatory barriers inhibiting cross-border on-line
ordering of prescribed as well as OTC pharmaceuticals, including product
categorisation, pricing and reimbursement policy, advertising and areas where the
principle of mutual recognition of national authorisations should be applied.
(c) The Commission should identify minimum standards of consumer protection and
safeguards to maintain public confidence in pharmaceutical products and their
distribution, in particular, in such fields as privacy, data protection,
security/encryption and liability issues.
(d) The Commission should consider launching an educational programme to alert
citizens of the risks related to the procuring of pharmaceuticals from non-reputable,
uncontrolled organisations, whether nationally or cross-border.
(e) The Commission should increase co-operation in global fora, with other governments
and professional organisations, to establish codes of conduct and co-ordinated
legislative frameworks that will assist the global provision of quality healthcare and
the establishment of instruments for the prevention of cross-border abuses of existing
pharmaceutical regulations.
2. %$&.*5281’
The increasing use by consumers of electronic means of communication such as the Internet has been
recognised in the EU by, for example, the Information Society Action Plan and more recently
in the public debate over electronic commerce. However, whilst the Information Society is
global in nature, an important part of the regulatory responsibility for pharmaceutical
products currently rests with individual EU Member States.  The tension resulting from this
is likely generally to hinder the realisation of a single market in pharmaceutical products and,
specifically, inhibits the use of electronic commerce for the supply of such products.
Further (and partly as a result), whilst electronic commerce is widely used at the business-to-business
level in the EU pharmaceutical sector, it is almost completely absent from the final link in the
chain - that of business-to-end-user - namely, between the pharmacist/wholesaler/
pharmaceutical company and the patient.  Normal competitive market dynamics are
encouraging the growth of E-commerce in all areas where the regulatory regime allows it.
Although concerns over security of data and shortage of technical skills act to slow those
dynamics, it is expected that E-commerce will continue to develop based on need and will
follow trends experienced in other business sectors.  The regulatory regime inhibits its use
currently at the retail level and therefore this study will concentrate on this aspect.
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3. 7+(&855(17326,7,21
3.1 (&3KDUPDFHXWLFDOV0DUNHWUHDOLWLHVRUKRZWKHPDUNHWZRUNV
(a) 5ROHDQGXVHRI(FRPPHUFHFXUUHQWO\
E-commerce is used currently by manufacturers principally in a business-to-business context
(largely through EDI).2  In particular, contracts between manufacturers and wholesalers are
often made electronically.  At the retail level, manufacturers’ web presences are largely
passive - providing only marketing and clinical information.  Outside the EU such
information provision has become widespread - indeed access to health information is now
the second most popular purpose for surfing the Internet in the US.  The use by wholesalers
and chains of pharmacists of E-commerce is, however, more restricted3 and seems to be
related to the size and sophistication of the business in question.  Some wholesalers provide
limited product information over the web and use EDI for transactions with pharmaceutical
companies and pharmacists4, but our survey found that in some EU jurisdictions this use was
still largely experimental.  Use by individual small pharmacists and patients for anything
other than information gathering is largely non-existent.  The exception to this relates to
some orders placed outside the EU - for which see the section on parallel imports in point (c)
below. The emergence of this non-EU market is evidenced by unsolicited bulk e-mailing of
EU citizens with material advertising pharmaceutical products.  An example of a recent
unsolicited e-mail is attached as Annex 7 to this study.
(b) ’LVWULEXWLRQFKDUDFWHULVWLFV
The distribution of pharmaceuticals in the EU is largely driven by the regulatory regime in
which it operates.  It currently takes place at three points - hospitals/surgeries, pharmacists
and other retail outlets.  The pharmaceuticals distributed may be divided into two categories:
"prescription" - which must be prescribed by a medical practitioner; and "over the counter"
("27&") - which need not be prescribed.
(c) 3DUDOOHOLPSRUWV
The purchase of pharmaceutical products from non-EU countries has always happened, even
though the importation of some pharmaceuticals in some countries might be illegal, at least if
not done directly by the patient5.  E-commerce, and more specifically the Internet, radically
increases the ability of patients to acquire pharmaceuticals from abroad, which causes
concern to manufacturers, wholesalers, pharmacists, health authorities and the medical
profession although for a variety of different reasons.
The market in pharmaceutical products is heavily regulated, in particular as to price, by each
Member State.  These regulations are intended to ensure that citizens have access to
pharmaceuticals of a minimum standard and that the cost of health care provision is
2
 Electronic Data Interchange. See Annex 6 - Section A of the survey results.
3
 See Annex 6 - Section A of the survey results.
4
 See, in respect of the UK, the Monopolies and Mergers Commission Report on the proposed merger of Unichem
and Lloyds Chemists - February 1992.
5
 The importation of medical preparations (which are authorised in the Member State of importation and are
available in that State without a medical prescription) which was purchased in a pharmacy in another Member
State by a private individual for his personal needs cannot be prohibited by national provisions - such provisions
are incompatible with Articles 30 and 36 of the EC Treaty (6FKXPDFKHU (C215/87) [1989] ECR 617).
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controlled.  Parallel imports in the pharmaceutical sector occur, for example, where
pharmaceuticals are imported from low price countries (such as Spain) into high price
countries (such as Germany or the UK) and thereby sold at a lower price than that of similar
non-imported pharmaceuticals6.
With the exception of the recent Viagra example, patients appear to have largely avoided
electronic commerce for the direct importation of pharmaceuticals; parallel trade has been
essentially restricted to up-stream, non-retail distribution.  However, the Viagra case has
made individual end-users aware of pharmaceutical distribution possibilities either because
products are not available in their own market or because the price in another market is
substantially lower. The obligation on suppliers not to provide  controlled pharmaceuticals
without a prescription will remain a deterrent to such imports, but Viagra showed that this
too could be overcome, though not necessarily in the best interests of the purchaser’s health.
(d) $YRLGDQFHHYDVLRQRIODZVDQGUHJXODWLRQV
In the EU, large scale commercial avoidance or evasion of pharmaceutical laws and
regulations is limited.  The whole thrust of the EU legislative regime has been to protect
consumers and patients from such exploitation.  There is however, some tension between EU
regulation and low grade private pharmaceutical importation (such as, for example, the
private import of melatonin, a product widely available in the US but, not in the EU) - the
scale of which is very difficult to assess.  The burden of enforcing Member States'
regulations in this area falls on national customs authorities and is likely to be rated as a low
priority for them.  Whilst there is no doubt that Internet access has the potential of increasing
the level of private importation, attitudes in certain Member States (e.g. Denmark) have
largely been to treat marketing on the world-wide web from sites based outside the EU as
extra-jurisdictional and therefore not subject to the EU regulatory regime.7  Consumers
taking advantage of such extra-jurisdictional marketing have therefore fallen within the
"private importation" exemption from restriction.  A more detailed discussion of these issues
is set out in Annexes 4 and 5 to this study.
3.2 0DUNHWWUHQGV
There is a growing trend, where authorised by law, for pharmacies to get together as a purchasing
group and acquire their product needs directly from manufacturers. There is also a trend for
wholesalers to acquire chains of pharmacies.  Economies of scale and distribution efficiency
are the primary drivers in a climate of diminishing returns for the wholesaler/independent
pharmacist.
Whilst some countries (particularly where the pharmacist lobby remains strong) remain unaffected by
this trend, most market observers believe the trend is unavoidable.  Government and health
6
 The ECJ has ruled that if a parallel importer supplies pharmaceuticals from one Member State in which market
authorisation has been lawfully obtained, the country of importation will infringe Article 30 EC if it subjects the
parallel import to a second authorisation or licensing procedure. See ’H 3HLMSHU, [1976] ECR 613 and more
recently, 5Y0HGLFLQHV&RQWURO$JHQF\H[SDUWH6PLWK	1HSKHZ3KDUPDFHXWLFDOV/LPLWHG, [1997] 1 CMLR
812.
7
 Manufacturers and regulators have found some non authorised vendors of pharmaceuticals beyond their reach -
for example, we understand that Pfizer, the manufacturer of Viagra, found that many unauthorised suppliers of
the product were providing (controlled) links to Pfizer’s own web-site to give their own marketing efforts an
appearance of legitimacy.  Although the use of such links would probably be considered an infringement of
copyright or trade mark rights in an number of jurisdictions (including the US and the UK), they were not
necessarily so recognised in the jurisdiction in which the web-site providers were based.
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insurance organisations’ pressure to reduce healthcare costs will force legislative changes
allowing more efficiency in the distribution of pharmaceuticals; this may result in a
reduction, albeit progressive, of the number of independent pharmacies.
Potential new modes of distribution are being considered by major market players, of which electronic
ordering is a strong contender.  Already most wholesalers are equipped with electronic
ordering systems and the fast delivery networks needed to support them.
As a result of the trend towards outsourcing, it appears unlikely that manufacturers will engage in
significant wholesale or retail distribution of their products, thereby leaving the wholesaler as
the principal link in the distribution process.  On the other hand, wholesalers (who over the
last few years have moved from a restricted, national presence to become large European-
wide operators) are now substantial market players.  While the physical delivery of
pharmaceuticals could remain organised on essentially a national basis, it seems inevitable in
the long run that the organisation of wholesale functions will eventually rest with a handful
of European groups.
Competitive pressure will induce cost savings8 and encourage improved distribution networks.
However, since there is at present in many Member States no flexibility in the final market
prices of prescription pharmaceutical products, competitive advantage at the wholesale/retail
level will principally come from the quality of service offered9 and improved economies of
scale.
In owning or controlling the retail distribution level (i.e. the pharmacies), the wholesalers will give
themselves a brand name and direct access to the patients as well as retailing skills.  They are
then well placed to offer the patients an array of new, additional services ranging from
simple electronic mail ordering to full healthcare management services.  There is no question
here of bypassing the pharmacies but, rather, of integrating both aspects of the
pharmaceutical distribution process and building on that synergy to create new added value.
Recent diversification of wholesalers in the home care market supports this view.
A parallel development to wholesaler concentration is the desire of governments and health insurance
organisations to encourage individuals to take responsibility for their own health and to
provide focused individual healthcare management.  The primary aim is the provision to
every citizen of better medical support through the improved recording and availability of
relevant information in individual patients’ files.  An equally important aim is the control of
healthcare costs.  Computer generated records of purchases of pharmaceuticals are one of the
data streams that would assist in meeting both aims. Prescription Benefits Management
(3%0), which produces such data streams, is one of the control tools that is therefore
likely to be put in place. Wholesaler access to PBM systems would allow a new range of
focused added value services to be marketed to healthcare providers.
Lastly, there is growing public acceptance of the Internet as an effective communications and
transaction medium. It is beyond the scope of this study to forecast the potential future
growth in Internet use, but it is worth mentioning in brief the success of the recent Parthenay
experiment in France, were access to E-commerce (groceries and household goods) has
8
 E.g. negotiation of prices with suppliers, economies of scale, efficiencies in warehousing and distribution,
reduction in inventory levels, etc.
9
 Note however that the UK currently operates a pharmaceutical pricing system linked to reasonable profits of the
pharmaceutical manufacturer- full details are set out in Annex 2.
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transformed a local online information service with a relatively low initial take up rate, to
one that exceeds the pre-launch estimates, thereby invalidating data about the country’s most
computer-averse population in the EU.
4. 327(17,$/)25(&200(5&(’(9(/230(17
4.1 $GYDQWDJHVDQGGLVDGYDQWDJHVRI(FRPPHUFHLQWKHSKDUPDFHXWLFDOVHFWRU
 
(a) 3DWLHQWV
Electronic prescription will require revised systems for pharmaceutical delivery - linking
doctors, pharmacies, social security systems and possibly patients.  This is already partially
achieved in hospital environments and also by the delivery of prescriptions from doctors to
pharmacists by facsimile.  Such new market mechanisms will hinge on regulatory changes in
the pharmacist-patient relationship.
For patients, the possible advantages of E-commerce can be grouped under the following
broad headings:-
 
• convenience: e.g. home delivery (especially for repeat prescription or long term
treatment of the acutely ill - see 4.2 below); wider choice of products10; more
public information available about a pharmaceutical; direct debit payments;
electronic handling of reimbursement and other paperwork;
• the availability of pharmaceuticals which are not marketed locally.
• speed of delivery;
• price differentials encouraging the acquisition of cross-border products at lower
prices (see section 6 below on cross-border E-commerce);
 
• cost reduction through economies of scale, PBM or use of generic substitutes;
The disadvantages that E-commerce could bring to patients include:-
• the machine interface - new skills are required and "the human touch" is lost (but
note the success of tele-shopping);
 
• the possible perception of a degradation in service levels (e.g. cycle time from
order to delivery) or costs (e.g. non-reimbursable delivery charges);
 
• risks perceived because of lack of security of payments or confidential
information, mishandling of personal data or unknown quality of products (where
generic substitutes used).
The net balance of perceived advantages and disadvantages will depend on each patient's
circumstances.
10
 The success of Amazon, the online book store, is an example of how extended product choice by comparison
with conventional competitors can be a key factor underpinning online sales success.
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(b) 3KDUPDFLVWV
Pharmacists are the only group who can legally provide a pharmaceutical sales service in
most EU countries.  The introduction of E-commerce into this environment is not possible in
many EU Member States due to regulatory restrictions11. With some adaptation of the
regulatory framework several aspects of the transaction could be successfully computerised.
However, pharmacists apparently see E-commerce as a force eroding their professional role
and status in the eyes of patients12.
For those pharmacists who embrace E-commerce, it could result in a more effective service
to their clients/patients, an extension of their market reach, and also some cost reductions in
inventory management, cash flow improvements and personnel requirements.
 
On the other hand, pharmacists would have to cope with a different approach to patient
contact (maybe by e-mail or telephone), invest in and then master E-commerce technology
and set-up a rapid delivery system that may well have to reach beyond their current
neighbourhood13. It is possible that such investment could only be economically justified if
pharmacists group together to provide sufficient critical mass. It is also likely that, in several
EU countries, this process will be vigorously resisted.
(c) :KROHVDOHUV
Wholesalers will, once authorised to sell direct to consumers, be best placed to offer the
range of electronic mail-ordering services that patients could ask for.  It is a logical extension
of their present activities - for which they have the technical and organisational know-how -
particularly those that already own chains of pharmacists with well-known brand names.
Wholesalers who do not have such pharmacist skills will need to acquire and brand them.
Such developments could further lead to cost advantages, part of which could be passed on to
patients, EU Member States or health insurance organisations.
(d) 3KDUPDFHXWLFDOFRPSDQLHV
The relationship between pharmaceutical companies and wholesalers is already highly
mechanised, using EDI or other electronic data systems.  The supply of information by
pharmaceutical companies to doctors is one of the most critical business flows in the
pharmaceutical sector - most pharmaceuticals would not be sold if not prescribed by a doctor.
Whilst on-line electronic data-banks of clinical information and some forms of electronic
mail may help the information process they will not, in the short to medium term, drastically
reduce the need for doctor visits by pharmaceutical company representatives, printed
information, symposia or other traditional means of conveying the medical relevance of
pharmaceuticals.  As doctors have little incentive in "pulling" the information, manufacturers
will have to continue to "push" it.
(e) 2WKHUV
11
 See Annex 1 to this study for a description of such restrictions.
12
 This is borne out by our survey results - for which see Annex 6 to this study.
13
 At least in the UK, pharmacists already accept orders and prescriptions by fax and deliver to patients.
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The role of social security systems and health insurance organisations (authorisation of
therapies, reimbursements of pharmaceuticals, etc.) varies vastly from country to country and
will be important in an analysis of the opportunities presented by E-commerce as they are
principal administrative agents of the health systems of most EU Member States.
High Street supermarkets and other retail stores currently offer some OTC pharmaceuticals
on their shelves in some countries.  E-commerce in this area would be a straightforward
extension of E-commerce already available today, or soon to be implemented, for non-
pharmaceutical product lines.
4.2 6SHFLILFH[DPSOHVRIHOHFWURQLFFRPPHUFHRSSRUWXQLWLHV
If regulations permit, there are sufficient potential benefits for consumers to encourage the
development of E-commerce in the pharmaceutical retail sector.  Set out below is a
non-exhaustive list of examples of how patients might benefit from the development of
E-commerce:
(a) /RQJWHUPWUHDWPHQWV
Where a patient is given a series of pre-programmed prescriptions to cover changing
requirements during a lengthy period of treatment, the prescriptions (if electronic) could be
forwarded (automatically or by the patient) to the E-mail-ordering supplier at each step of the
treatment (this already occurs by facsimile in the UK).  Alternatively, the supplier could
administer the series of shipments on behalf of the patient, possibly even with medical
follow-up on behalf of the prescribing doctor (e.g. as part of a Home Healthcare Management
System).
(b) &KURQLFGLVHDVHVRUUHSHDWWUHDWPHQWV
Refill prescriptions could be registered once with the E-mail-ordering provider, and triggered
if and when needed by the patient.  No further prescriptions would be required.  With the
advance of electronic certification based on cryptography, the prescription could be
registered with a mutually recognised certified ‘clearing system’ and the patient would be
able to get the medicine simply by quoting a verifiable reference number.
(c) (OGHUO\KDQGLFDSSHGGLVDEOHG
Rather than being dependant on others, these patients could take advantage of E-mail
prescribing and ordering combined with home delivery
(d) 5HPRWHUXUDODUHDV
As already practised in Nordic regions, patients with difficult access to pharmacies (because
of distance, road conditions or lack of public transportation) would benefit from E-mail
prescribing and ordering combined with either home or pick-up point delivery
(e) :RUNLQJKRXVHKROGV
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In line with developments in the grocery and household goods retail sector, members of a
working household would welcome the possibility to order pharmaceuticals on-line and get
delivery outside usual working hours at a convenient pick-up point
(f) &RPSXWHUFHQWUHGSXUFKDVHUV
The development of electronic commerce will create a new class of purchasers that will
almost exclusively purchase on-line.  For many, pharmaceutical needs will be no different
than other product lines and they will therefore seek to purchase pharmaceutical products
on-line.
(g) /RZLQFRPHSDWLHQWV
Where patients presently have to claim reimbursement after the purchase of pharmaceuticals,
electronic commerce could provide links with health insurance organisations that would
avoid them having to reclaim urgently needed cash.
4.3 ([SHULHQFHVLQRWKHUFRXQWULHV
The country which has most experience of E-commerce in the pharmaceutical industry is the US. A
description of the US pricing controls, regulatory system and advertising regulations are set
out respectively in Annexes 2, 3 and 4 to this study.
Having conducted extensive surveys of interested parties in relation to Internet trading, the FDA14 has
stated publicly (last month) that it considers the Internet just another promotional medium.
Consequently, they argue that little new regulation is required in the US to regulate the on-
line market.  This has been borne out by their experience of on-line infringement, which has
followed the same pattern as violations in traditional media.  Typically these include
misleading claims and lack of fair balance in describing risks and effectiveness.
While the FDA has yet to publish full guidance on its attitude to marketing and sales on the world
wide web, they have already issued warning letters to companies setting up web sites which
they consider infringe US legislation.  Given US practice to date it seems likely the FDA will
also take an aggressive jurisdictional line on sites based outside the US but available to US
consumers.
5. %$55,(5672(/(&7521,&&200(5&(
E-commerce will require, for most EU Member States, a review of the regulatory
environment under which pharmaceutical products are offered for sale to patients. Our
survey of market participants raised issues relating to the provision of quality healthcare, the
protection of the patient’s health as well as his or her privacy, the abuse of pharmaceutical
consumption and the potential negative impact of E-commerce on local communities (given
the likely decline in the number of neighbourhood pharmacists and doctors).  On the other
hand, the development of E-commerce could be viewed as a natural evolution of current
practices and, therefore, easily subject to the same high quality professional care and
appropriate regulatory safeguards.  Some of the problems which the current regulatory
regime in EU Member States raises in relation to E-commerce are set out below.
14
 Food and Drug Administration.
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5.1 5HJXODWRU\FRQVWUDLQWV
(a) 7KHGHILQLWLRQRI‡27&·DQG‡SUHVFULSWLRQ·
Pharmaceuticals may be divided into four categories, determined by the regulatory
requirements imposed upon them.  These determine how and where such pharmaceuticals
may be purchased and how they may be paid for. Although the specifics of each category
vary from country to country15, the categories may broadly be described as follows:-
• prescription pharmaceuticals which are restricted to hospital use (most are fully or
partially reimbursed);
• prescription pharmaceuticals which are distributed through pharmacies (most are
subsidised);
• non-prescription or over-the-counter (27&) pharmaceuticals which are
distributed through pharmacies only (generally not subject to reimbursements but
could be subsidised or partially reimbursed when specifically prescribed by a
doctor or if they are part of a reimbursable treatment); and
• OTC pharmaceuticals distributed through retail outlets (in principle not
reimbursable).
These distinctions may be incompatible with the sale of such pharmaceuticals electronically.
 
(b) 0DUNHWLQJDXWKRULVDWLRQV
A pharmaceutical product cannot be put on the market in a Member State without a
marketing authorisation.  As it is practically impossible to restrict access to Internet sites to
the residents of a particular Member State, the following situations are possible:
(i) inter-EU - a prescription pharmaceutical product which has a marketing
authorisation in one Member State is marketed on the Internet and is accessed
in another Member State where the product has not obtained a marketing
authorisation;
(ii) inter-EU - a pharmaceutical product which is considered as OTC in one
Member State is marketed on the Internet and is accessed in another Member
State where it requires a prescription;
(iii) extra-EU - pharmaceutical products which are authorised in countries with a
well respected medicines agency (e.g. the US) are marketed on the Internet
and accessed in Member States where the pharmaceutical product is not
authorised; and
 
15 
  New products approved through the European procedure (EMEA) will henceforward be considered either
prescription or non-prescription for the whole of Europe.
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(iv) extra-EU - pharmaceutical products which are authorised in countries without
a well respected medicines agency are marketed on the Internet and  accessed
in a Member State where the pharmaceutical product is not authorised.
One way of dealing with all the above cases would be to make it clear to Internet users
whether or not the particular pharmaceutical product is approved by the medicines authorities
in any particular country and whether the sale of a pharmaceutical product is equivalent to a
private importation of pharmaceutical products. This could be done by a statement on the
web-site which precedes any details relating to the pharmaceutical product or to the actual
purchasing process and which must be ’accepted’ by the Internet user before proceeding (like
a "click wrap" procedure).
Another way would be to look more closely at the whole issue of the regulation of marketing
authorisations themselves to determine issues such as:
(i) whether or not a ’mutual recognition’ of marketing authorisations could be
established, for E-commerce purposes, between Europe and other countries
with well established regulatory regimes, such as the US.  Such a centralised
“Mutual Recognition” procedure could go some way towards also achieving a
parallel “mutual recognition” within Europe itself; and
 
(ii) whether marketing authorisations could include provisions which permit
marketing through the Internet. The Internet marketing authorisation
provision could relate to specific web sites, which could easily be inspected
by the competent authorities and reciprocity clauses could be provided to
ensure uniformity in respect of non-EU countries
Whilst it is beyond the scope of this study to deal with all regulations which may be affected
by E-commerce, consideration may need to be given to amending current regulations so as to
deal with, for example, pharmaceutical companies granting exclusivity to import products in
certain countries only through the Internet, thus creating a niche of Internet distribution
parallel to traditional distribution channels.  Furthermore, enforcement in a cross border
environment will fall increasingly on state customs authorities raising government costs, in
the face of a commensurate decline in domestic sales tax revenue.
Finally, it may be important to determine whether the liabilities which attach to the holder of
a marketing authorisation for the marketing of pharmaceutical products can also apply to the
party who actually resells the pharmaceutical product through the Internet.  This raises issues
of content responsibility and the liability of others (such as an Internet service provider)
should the content be misleading.
 
(c) 7KH3KDUPDFLVWV
PRQRSRO\
 
The medical responsibility for the delivery of a prescribed pharmaceutical lies with the
prescribing doctor. The pharmacist's input is generally limited to usage recommendations. In
contrast, the legal responsibility of the pharmacist is to ascertain that there is a prescription
when required, that the patient is eligible for reimbursement or subsidy for any given
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purchase16 and to comply with the administrative requirements of the reimbursement
systems17.
In addition, throughout the EU Member States, in particular in relation to OTC
pharmaceuticals, pharmacists have a counselling role that is perceived as highly critical with
regard to public health protection. This role has however largely disappeared in respect of
household-type products such as aspirin, common cold medicine or first aid kits, that
consumers consider little different from hygiene or skin-care products. Nevertheless, the
pharmacists’ monopoly is still prevalent in several countries (e.g. Italy) even for the
distribution of this latter category of pharmaceutical products.
Whilst the counselling role may now seem inappropriate given the increased levels of
education and self-responsibility attained by citizens of EU member states, both currently
constitute barriers to the successful use of E-commerce in the pharmaceutical sector.
(d) $GYHUWLVLQJSURPRWLRQDQGODEHOOLQJ
A summary of advertising restrictions on pharmaceutical products is set out in Annex 4 but,
in short, the current regulatory regime operates on the basis of both national and international
regulation.  Despite the substantial acceptance of international standards adopted by the
WHO and IFPMA, nearly two thirds of the world’s countries still do not have laws to
regulate pharmaceutical promotion or do not enforce those that they have.
In the EU, regulation has followed a substantially more rigorous line than in the US where
indications and counter-indications, medical effectiveness, dosage, side effects, and even
sometimes price information can already be found on web sites for many popular products. It
is becoming increasingly unacceptable for a patient to be denied access to information that
could help him assess and discuss with his doctor possible alternatives to his prescribed
treatment. However, the difference between valuable information and promotional material is
sometimes difficult to define; in these circumstances the protection of the consumer from
misleading information as to pharmaceutical products is clearly important. Regulatory
authorities will need to provide recognised standards for vetting and approving the
disseminating of such information.
European Community law prohibits the advertising of prescription-only pharmaceuticals to
consumers (whether by web-site or otherwise) whereas US law does not. Clear forms of
approved wording (such as those used in the advertising of financial services) could enable
compliance with territorial or EU regulations without restricting business enterprise. In
addition, regulators may consider that certain kinds of OTC pharmaceuticals could be
commercially distributed and as a result revise rules in order to allow these products to be
more freely advertised and promoted.
16
 Some insurance plans do not cover all reimbursable pharmaceuticals and some reimbursements are conditional
upon specific authorisations - with time and/or quantity restrictions - by the health insurance organisation.
17
 There are situations where patients have to claim reimbursement themselves, however this is generally on the
basis of documentation provided by the pharmacist.
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(e) ’HOLYHU\
 
Technological developments raise questions about potential new forms of product
distribution.  As an example, is there any real distinction between a computer order placed by
a patient at his neighbourhood pharmacy (whether for pick-up by himself or for home
delivery) and the same order placed by phone or fax (as already occurs) or using a set-top
box and television?  Would this be considered distance selling and/or tele-shopping?
Distance ordering and mail ordering where the patient "pulls" the commercial information,
must be clearly distinguished from commercial offerings where the seller "pushes" the
information to the consumer.
Given that one of the major advantages of the Internet is its global reach, Article 14 of the
Distance Selling Directive, which entitles Member States to prohibit any distance selling of
pharmaceutical products on their territory, or the overall ban on tele-shopping for
pharmaceuticals will, arguably, give a competitive advantage to other countries such as
Switzerland and the US.  Patients will seek to access such markets, for example where there
are clear price or quality differentials, or where highly publicised pharmaceuticals as yet
unlicensed or otherwise unavailable in the EU are readily available by mail order.
(f) 3ULFLQJDQGUHLPEXUVHPHQWV\VWHPV
(i) Pricing
Current price differentials discourage industry support for pharmaceutical trading on the
Internet.  On the commercial front, Internet trading makes cross-border price differentials
much more transparent, increasing the opportunities for parallel trading - already a
significant concern for the pharmaceutical industry. The introduction of the Euro will further
increase the transparency of prices and the effects of sales tax.
In theory, suppliers could be forced to vary the price of the product on offer depending on the
location of the customer who has accessed their web-site.  Legally, if they fail to observe
national pricing restrictions (applicable to prescribed pharmaceuticals), the supplier may be
subjected to scrutiny and prosecution by the national bodies responsible for policing the
pricing system.  Their products may also be liable to be seized by customs officials on the
way to market.
Alternatively, the relevant authorities may take the view that the supplier is free to price
products on a web-site according to the pricing restrictions in the territory in which the server
is located. This would enable suppliers with web-sites in, for instance, the US, where there
are no (or very few) restrictions on pricing, to offer pharmaceuticals for sale at whatever
prices they choose and can commercially maintain.  This is subject to the problems caused by
national reimbursement systems which are discussed in detail in Annex 2 to this study -
specifically who would reimburse the patient (if anyone) and with how much?
- 14 -
(ii) Reimbursement
Patients under most healthcare/social security systems in the EU have the costs of their
pharmaceuticals subsidised by a method of reimbursement by the State.  Reimbursement
works in at least three ways: either the consumer (as in France) or the pharmacist (as in
Belgium) claims directly his reimbursement or the supplier claims his reimbursement on the
back of a sale (the UK system). All systems are designed to operate only within that Member
State’s borders, though the cases discussed in more detail at Annex 2 show how that may no
longer be appropriate.
Reimbursement, together with the issues of product categorisation and pricing, may affect the
development of E-commerce, in particular with respect to prescribed pharmaceuticals, by
influencing the cost considerations of the patient.   Member States’ price and reimbursement
systems could hinder free competition in the EU market for pharmaceuticals by encouraging
certain purchases from only certain jurisdictions.
5.2 /HJDOUHVWULFWLRQV
In addition to the regulatory constraints identified above, the following legal restrictions, many of
which are of horizontal nature, can be considered as barriers to E-commerce in the
pharmaceutical sector:
(a) -XULVGLFWLRQDQG$SSOLFDEOHODZ
Jurisdiction is one of the more vexed legal issues relating to the Internet. Which country's
law is to apply to an infringement of medicines regulations or intellectual property rights
resulting from an offer for sale made on the Internet?  It is far from clear to what extent the
mere fact of having a web-site will subject the site owner to the laws of that given country.
At present each case must be considered on its own facts and, in many instances, the answer
will depend upon the laws in the country in which the question is being raised.  However,
due to a lack of international conventions dealing specifically with cross-border Internet
related transactions, national courts are having to adapt traditional concepts of jurisdiction,
including the need to establish first where the infringement occurred and secondly which
country has jurisdiction over that infringement.  There is also scope for national courts to
interpret the European conventions inconsistently, even those intended to harmonise national
laws.
The international dimension of E-commerce raises issues as to which law will govern the
relationship between the parties in question, whether all legal requirements for forming a
valid contract have been met and the difficulty of identifying terms and conditions which
underpin the transaction18.
National legal systems have differing requirements as to ZKHQ and consequently ZKHUH a
contract is formed and the necessary factors for validity and enforceability. For example,
some jurisdictions place severe procedural restrictions on the sale of goods unless documents
are signed by hand (calling into question the effect of digital signatures), while others require
18
 The European Commission proposed, on 18 November 1998, a draft Directive on Legal Aspects of Electronic
Commerce, which covers areas such as jurisdiction and liability ( See Commission press release IP/98/999).
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contracts to be in the local language of the country where the customer is located.  Local
consumer protection laws will also affect the contractual relationship and its validity.  These
laws apply as much to contracts involving the sale or supply of pharmaceuticals as to any
other product or service.
While many academic commentators seem to agree it is open to an on-line trader to state
clearly those terms and conditions (including the applicable law) which will govern the
parties’ relationship and asking the customer to accept these prior to placing an order, it still
remains to be seen how different national courts will deal with such situations; harmonising
legislation may therefore be required.
The issue of liability is similarly problematic, whether it be contractual, civil, regulatory
etc.19, particularly in the context of identifying the jurisdiction where loss, damage or
penalties have been suffered.  These issues remain unresolved, although the draft directive on
electronic commerce20, published on the day of this report, addresses the question of liability,
by removing liability from service providers where they are providing “conduit services”
only.  In relation to web-site providers, they will, it is proposed, be regulated on the basis of
the laws applying in their place of economic activity. It remains unclear how this will afford
consumer protection (even allowing for mutual recognition of consumer protection laws
between EU Member States) where the origin of web-sites is unclear, or where the site
provider is multi-national in nature (as is common in the pharmaceutical market).
(b) 3ULYDF\
The European Data Protection Directive21 attempts to harmonise data protection legislation
throughout the EU.  The Directive regulates the processing of personal data (including data
relating to patients - such as health records - suppliers and doctors) and focuses on the
security of personal data and the right of individuals to be informed of, and object to the use
of, their data.
EU legislation is more restrictive than most other countries in respect of data protection
legislation, and the Directive includes a provision prohibiting the transfer of personal data
outside the EEA to countries which do not have adequate levels of data protection.  Two of
the most significant countries which might be considered not to have adequate levels of data
protection are the United States22 and Japan.  Clearly this has consequences for electronic
commerce in the pharmaceutical sector since personal data is likely to be transferred outside
the EEA to vendors of products and data controllers have little control over the route data
takes between the two parties.
The Directive also distinguishes a category of personal data as "sensitive" which includes
information as to the physical or mental health of individuals. Where sensitive personal data
is processed there are more stringent conditions to comply with.  For instance, in order to
19
 In the context of E-commerce in the pharmaceutical sector, liability may arise in relation to the on-line
prescription by the electronic doctor, in relation to the pharmacist’s advice on OTC, in relation to the quality or
effect of pharmaceuticals provided and in relation to non-delivery or late delivery of the pharmaceutical products.
20
 See press release reference IP/98/999
21
 Directive 95/46/EC of 24 October 1995 on the protection of individuals with regard to the processing of personal
data and on the free movement of such data, OJ 1995 L 281/31.
22
 Negotiations on a ‘Safe Harbour’ are currently ongoing with the US, and although the implementation period set
for the Data Protection Directive ended on 24 October 1998, there is an understanding that pending the
conclusion of the negotiation, the Directive would not be used against US companies.
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process information such as patients’ health information, the data controller will have to
obtain the explicit consent of the patient for the processing.
These conditions will in particular apply to pharmacists and doctors attempting to consider
medical records or patient medical information and then prescribing electronically on the
basis of that information or supplying according to such prescriptions23.  The clear consent of
participants in such an electronic health care environment would be required in order for data
relating to them to be manipulated.
(c) ,QWHOOHFWXDO3URSHUW\3URWHFWLRQ
(i) Copyright
The transmission of material over the Internet could infringe the copyright of a third party.
Problems arise in determining who to sue (e.g. the service provider, the host server or the
third party accessing the material, each of whom could "copy" a copyright work) and where
jurisdiction lies.  Current case law is unclear and it is arguable whether the position as
clarified in relation to copyright jurisdiction in respect of, for example, satellite broadcasting
(i.e. the "country of origin" principle) can as easily be applied to E-commerce transmissions
on the Internet, which can be copied and re-copied in transmission to millions of users in
many different countries, thus making it in practical terms difficult to trace the country in
which the message originated.
(ii) Patents
Patent law throughout the Community is relatively harmonised.  In relation to E-commerce
and the pharmaceutical industry, it is likely that most issues of patent infringement will arise
as a result of parallel importation from a country with no patent protection to one which has
(the law relating to which is well recognised) or in relation to the offering to dispose of
products or offering a process for use over the Internet (or both).  In relation to the second
point, the jurisdictional problems are familiar, for example whether or not the receipt of an
offer of sale of a product which is legal in the country of origin, but which happens to be
accessed in a country where such offer infringes the patent rights of a third party, constitutes
patent infringement.  The position is complicated by the position that, despite harmonisation,
the decisions of national courts within the EU can conflict.  The position in relation to E-
commerce patent infringement may benefit from guidelines as to what constitutes patent
infringement on the Internet.  It may also benefit from a Unitary Court structure and
procedure at community level for resolving litigation, as is anticipated by the Community
Patent Convention.
(iii) Trade Marks
Trade mark rights are of particular importance to the pharmaceutical industry.  The main
problems raised by the use of E-commerce in relation to trade marks are, first, those raised by
the likely increase in parallel importation (the law relating to which is well known) and,
second, that the inability to control access could result in trade marks being 'used' in
countries where such use may amount to an infringement of a third party's rights, or may be
23
 The recent viagra case is an example of a situation in which EU citizens have provided personal information to
US on-line doctors in order to obtain a prescription for Viagra.
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illegal for some other reason.  Potentially, an infringing act can be committed in any country
from which a web site can be accessed and where there are either trade mark registration
rights or rights due to use.  The continuing success of the Community trade mark and Madrid
routes, together with use of a single trade mark to market a given pharmaceutical product
throughout the EU (as opposed to different trade marks in different countries) may help to
lessen trade mark infringement problems on the Internet.  However, the essentially national
nature of trade marks means that infringement issues are inevitable unless world-wide trade
mark protection is obtained by pharmaceutical companies.  As this would be costly and
impracticable, other methods of defences to trade mark infringement on the Internet, such as
statutory recognised disclaimers in respect of countries where it is not intended to use a
particular trade mark, may need to be considered.
(iv) Confidential Information
The main problem with regard to the transmission of confidential information over the
Internet is lack of security, coupled with the difficulty of establishing an express contractual
obligation of secrecy with parties such as Internet service providers or third parties who are
able to access such information in transmission, or by chance, and pass it on.  Protection
options for pharmaceutical companies at the moment include the use of encryption, clear
notices informing recipients of the information that there is an obligation of security in
respect of it, and the use of Intranets to exchange confidential information between
authorised users only.
5.3 7HFKQLFDOEDUULHUV
(a) 6HFXULW\RILQIRUPDWLRQDQGHQFU\SWLRQ
Among the now traditional objections to Internet-based transactions (whatever their nature)
is the potential accessibility by third parties of personal and financial information of those
conducting the transaction and the subsequent use or abuse of that information.  In the
context of this study, the personal information involved is the private medical information of
the patient - which may include past medical records - and financial information,  i.e. bank
account details, debit/credit card details, smart card details etc.
At present there seem to be few technical barriers to maintaining the security of the
necessary data.  While no encryption method is likely to be perfectly secure, the ever
increasing complexity of encryption methods seems to provide adequate security for all
practical and commercial purposes (and they are a good deal more secure than passing the
same information by fax or telephone).  The introduction of Secure Electronic Transactions
(SET) - an accepted payment protocol - signifies a recent advance and a clear confirmation,
currently evident in the realm of business-to-business transactions, that adequately secure
methods of dealing with financial information can and do exist.  The issue of personal
information may be a more sensitive one, though the obvious advantages of accessing
medical records instantly from anywhere in the world may help the public to accept any risks
that may exist.
Other electronic security devices include digital signatures and digital watermarking.  Thus,
digital watermarks in electronic prescriptions should make it more difficult to re-use or
reproduce prescriptions.  As any original digitally watermarked electronic prescription is
capable of uniquely identifying a doctor, prescribed pharmaceutical or patient, the
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traceability of any abuser should act as a deterrent.  The proposed use of licensed trusted
third parties for the actual transmission of the encrypted data, and the potential requirement
for recognised digital signatures to access personal data should allay most rational fears.
(b) ,QWHUQHWSHQHWUDWLRQ
Assessing levels of Internet penetration with precision faces two problems.  Firstly, methods
of measuring penetration depend on survey evidence.  Secondly, such is the speed of growth
of online use that such figures are frequently out of date almost the moment they are
published.
A number of general statements can however be made about Internet access availability and
E-commerce volume.  Firstly, to date growth has been "exponential" since the first use of the
world-wide web.  Secondly, penetration in the US has now exceeded 40% of the population
and is showing initial signs of a reduction in the rate of growth.  Third, whilst take-up in
Europe and South-East Asia has lagged behind the US - it appears to follow the same pattern
of growth.  Penetration rates in the major economies of Europe average between 7 and 10%.
Penetration in both the US and Europe show a marked age, sex and education variation.  The
typical purchaser of online services is 36, male, relatively wealthy and has been through
higher education.
Irrespective of what level of penetration Internet access finally reaches it is likely therefore
that some parts of society will not gain access to the Internet - whether by choice or through
lack of resources.  Typically, they will be the elderly the uneducated and the poor.  Several
respondents to our questionnaire raised concerns that E-commerce would create a "two class
society" divided by whether or not they had access to online facilities.  Whilst this certainly
is likely to occur, it is no different from the historical development of other products which
have become commonplace over time such as television or the telephone.
(c) %DUFRGLQJ
Bar codes on pharmaceutical packets contain country specific segments of code.  These vary
from jurisdiction to jurisdiction and are used for a variety of reasons, including
pharmaceutical details and social security information.  Whilst this issue will not concern the
consumer, small pharmacy chains or health organisations who source pharmaceuticals
outside their own jurisdiction may find their stock bearing codes that are inappropriate for
their own jurisdiction.  However, some purchasers will be able to negotiate re-labelling of
bar codes or alternatively be able to resource the production of alternative bar code labels
internally once the goods have arrived in the purchaser’s jurisdiction - although the latter
could not be done in a manner which affected the ability of the manufacturer to identify the
production batch of the products in question for product recall/liability purposes.  It is worth
mentioning that no respondent to our survey raised bar codes as a potential hindrance to E-
commerce.
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6. (/(&7521,&&200(5&($&52661$7,21$/%25’(56
6.1 :KRZRXOGRUGHUDEURDG"
The situations where this may happen fall under the following four categories.
(a) 7KHFURVVERUGHUWUDYHOOHU
Cross-border travellers that have forgotten, run out of or lost their usual medication could
ask, on-line, for a fast delivery to the cross-border country where they are staying. Such
cross-border travellers may well prefer to obtain their usual medication in this way, rather
than use local pharmaceuticals that they do not normally use and are not familiar with.  This
would also allow travellers to consult their local doctor (in their jurisdiction) and use their
home pharmaceutical retail system, in both cases in their own language and with which they
are consequently much more comfortable.
(b) 7KHWHPSRUDU\FURVVERUGHUUHVLGHQW
Typically, these patients will remain registered with their home doctor and remain affiliated
to a home-based health insurance organisation.  Outside of emergencies, they have no
incentive to comply with local practices.  Mail or online ordering of their pharmaceutical
requirements would seem perfectly logical, if the capability exists to obtain pharmaceuticals
from their home country and would seem to be attractive, unless there were significant cost
penalties.
This approach could probably be extended to all pharmaceutical products, prescription or
not, that the patient is used to being supplied with (i.e. "household" medicines, homeopathic
preparations etc.).  As with travellers, their ability to also use their own language would be a
further incentive.
(c) 7KHORQJWHUPFURVVERUGHUUHVLGHQW
These patients would be much more likely to register with a local doctor and become
affiliated with a local health insurance plan.  The appeal of purchasing some of their
pharmaceutical needs from their home country, besides the ability of using their own
language, would be more likely to depend on the same considerations as apply to a national
resident.
(d) 7KHQDWLRQDOUHVLGHQW
The most obvious circumstances in which national patients are likely to use electronic
ordering to acquire pharmaceuticals from abroad are as follows:
(i) e-commerce is not available for ordering pharmaceuticals from suppliers in
their own country;
(ii) the pharmaceutical is not available in their country and there are no adequate
substitutes. The recent Viagra example falls into this category;
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(iii) the pharmaceutical is (much) cheaper abroad. The incentive will increase
depending on the net price differential, after reimbursement and the length of
treatment; or
(iv) the patient’s knowledge that it is not subject to a prescription or other
restrictive regulation in another country.
Cases (a) to (c) above would not appear to be of major concern to health authorities or the medical
profession, as in each case the cross-border patients are following practices that are locally
acceptable in their home country.  Case (d) may be more concerning to the country involved,
since such private importation of unregulated pharmaceuticals is contrary to the regulatory
and legislative system that have been established to control pharmaceutical use in that
patient’s jurisdiction.
6.2 &RXOGWKHULVNVUHODWHGWRFURVVERUGHUSXUFKDVHVEHUHGXFHG"
The inability of national regulators and enforcement agencies to control cross-border operators raises
some interesting questions regarding what practical measures that could address the main
issues.
(a) The first question is whether it is possible to reduce the attractiveness of ordering
pharmaceuticals from abroad.  Three actions could help:-
(i) provide (competitive) electronic commerce domestically;
 
(ii) establish greater harmonisation in product categorisation (namely prescription,
OTC and retail pharmaceuticals) and brand names on a European or global
basis (and in particular with neighbouring countries); and
 
(iii) seek to avoid large price differences from country to country for reimbursable
products and leave prices free to adjust to market forces for other products.
(b) The second question is whether there is a public health concern if patients order
pharmaceuticals from a reputable cross-border organisation which has received
market approval from a recognised medicines agency.  Though the rules and
regulations under which they operate may be different from those of the country of
the purchaser, this does not necessarily mean that purchasers are likely to put
themselves at risk.  If it can be established that the local organisations use the same
code of conduct for domestic and cross-border deliveries, rules of reciprocity can be
applied. It may be that the problem can be reduced by the proper identification of the
reputable organisations in each country, which can be resolved by co-operation
between the respective national authorities and by ensuring liability for defective
products falls on the company at fault.
(c) The third question is whether illicit suppliers can be discouraged. Taking the
economic incentive away must be the preferred long-term solution.  Again two
courses of action could be considered:-
(i) improved global co-ordination of product categorisation, together with an
attempt at the reduction of price differences, would reduce economic
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incentives.  Improved  tracking of product distribution, to trace how
pharmaceuticals are distributed and through what channels, might also be a
deterrent; and
 
(ii) a parallel approach would be to attempt to reduce demand through concerted
educational programmes for patients, stressing the potential problems of not
dealing with approved suppliers, whether nationally or internationally.  Some
form of CE marking of approved online suppliers might assist this - such CE
marks could be hypertext linked to the list of approved online suppliers kept
by the relevant national regulatory body (hence preventing illegitimate
suppliers simply copying the CE symbol without approval).
(d) The fourth question is whether pharmacists in one country should be able to accept,
as discharge of their legal duty, a prescription issued in another country (or one given
online by an online doctor) and whether such a prescription would entitle
reimbursement of the patient, pharmacist or supplier (depending on the type of
national system).
(e) The fifth question is how to counter the willingness of some doctors - or fraudulent
operators - to deliver (electronic) prescriptions without regard to the genuine
requirements of the patient.  This is a problem that exists already and has proved
difficult to counteract.  Nevertheless with technology such as electronic
watermarking and electronic signatures available, whilst the possibility of copying a
true prescription to form a forged or fraudulent one remains, it could be easier to
track such fraudulent prescriptions because of the complex "data-trail" left by
electronic prescriptions (in PBM systems for example).
7. &21&/86,216$1’5(&200(1’$7,216
E-commerce is already extensive in Europe in the business-to-business market place and, on
a small scale, between vendors outside the EU and patients.  Whilst it does not currently take
place between European vendors of products and patients to any significant extent, the desire
for such a market undoubtedly exists.  If that market is to operate effectively the EU will
need to address the issues of price inequalities between Member States, reimbursement,
parallel imports, advertising and marketing regulation, the future role of pharmacists and,
perhaps most importantly, how to ensure continued public health and public confidence in
the pharmaceutical supply system.
In the light of the above, we propose the following tentative recommendations:
(a) In considering the adoption of any policy on the impact of electronic commerce on
the European pharmaceutical sector, the Commission should recognise:-
(i) the global nature of the Internet;
(ii) the importance of public funding and the health insurance industry;
(iii) the producers’ and wholesalers’ drive for continued cost reduction in
pharmaceutical distribution; and
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(iv) the opportunities to benefit the retail distribution chain as a whole from doctor
through pharmacist to patient.
(b) The Commission should review the regulatory barriers inhibiting cross-border on-line
ordering of prescribed as well as OTC pharmaceuticals, including product
categorisation, pricing and reimbursement policy, advertising and areas where the
principle of mutual recognition should be applied.
(c) The Commission should identify minimum standards of consumer protection and
safeguards to maintain public confidence in pharmaceutical products and their
distribution, in particular, in such fields as privacy, security/ encryption and liability
issues.
(d) The Commission should consider launching an educational programme to alert
citizens of the risks related to the procuring of pharmaceuticals from non-reputable,
uncontrolled organisations, whether nationally or cross-border.
(e) The Commission should increase co-operation in global fora, with other governments
and professional organisations, to establish codes of conduct and co-ordinated
legislative frameworks that will assist the global provision of quality healthcare and
the establishment of instruments for the prevention of cross-border abuses of existing
pharmaceutical regulations.
- 23 -
$11(;
6XPPDU\RIUHJXODWLRQRIUHJLVWHUHGSKDUPDFHXWLFDOFKHPLVWV
1. 8.
1.1 *HQHUDO
The registration and general control of registered pharmaceutical chemists ("SKDUPDFLVWV"),
are the responsibility of the Pharmaceutical Society of Great Britain (the "6RFLHW\"), of
which all pharmacists have to be a member.
Under UK law the primary national legal regulation of  pharmacists is included within the
Medicines Act 1968 ("0 $ "). There is also a specific Act providing additional
regulation for pharmacists, namely the Pharmacy Act 1954, which addresses the
membership, and disciplinary and other powers of the Society.
1.2 3URKLELWRU\IUDPHZRUN
The M A 1968 creates the foundation of a prohibitory framework:-
([FHSW LQ DFFRUGDQFH ZLWK D SURGXFW OLFHQFH RU PDUNHWLQJ DXWKRULVDWLRQQR SHUVRQ
VKDOOLQWKHFRXUVHRIDEXVLQHVVFDUULHGRQE\KLP
D VHOOVXSSO\RUH[SRUWDQ\PHGLFLQDOSURGXFWRU
E SURFXUHWKHVDOHVXSSO\RUH[SRUWDWLRQRIDQ\PHGLFLQDOSURGXFWRU
F SURFXUHWKHPDQXIDFWXUHRUDVVHPEO\RIDQ\PHGLFLQDOSURGXFWIRUVDOHVXSSO\RU
H[SRUWDWLRQVHFWLRQ0$
"Medicinal product" is defined broadly to mean any substance or article (not being an
instrument, apparatus or appliance) which is for use by being administered to one or more
human beings for a medicinal purpose or as an ingredient for such.
"Medicinal purpose " is defined broadly to include inter alia treating or preventing disease,
diagnosing disease and inducing anaesthesia.
"1RSHUVRQVKDOO LQ WKHFRXUVHRIDEXVLQHVVFDUULHGRQE\KLPPDQXIDFWXUHRUDVVHPEOH
DQ\PHGLFLQDOSURGXFWH[FHSWLQDFFRUGDQFHZLWKDOLFHQFHsection 8(2) M A 1968
1.3 3KDUPDFLVWVPRQRSRO\
Section 10 M A 1968, however, exempts pharmacists from the prohibitory framework of
section 7 and 8:-
"VHFWLRQV  DQG  RI WKLV $FW GR QRW DSSO\ WR DQ\WKLQJ ZKLFK LV GRQH LQ D UHJLVWHUHG
SKDUPDF\DKRVSLWDORUDKHDOWKFHQWUHDQGLVGRQHWKHUHE\RUXQGHUWKHVXSHUYLVLRQRID
SKDUPDFLVWDQGFRQVLVWVRI
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(a) SUHSDULQJ RU GLVSHQVLQJ DPHGLFLQDO SURGXFW LQ DFFRUGDQFHZLWK D SUHVFULSWLRQ
JLYHQE\DSUDFWLWLRQHURU
E DVVHPEOLQJDPHGLFLQDOSURGXFWSURYLGHGWKDWZKHUHWKHDVVHPEOLQJWDNHVSODFHLQ
DUHJLVWHUHGSKDUPDF\
L LWVKDOOEHLQDUHJLVWHUHGSKDUPDF\DWZKLFKWKHEXVLQHVVLQPHGLFLQDO
SURGXFWV FDUULHG RQ LV UHVWULFWHG WR UHWDLO VDOH RU WR VXSSO\ LQ
FLUFXPVWDQFHVFRUUHVSRQGLQJ WR UHWDLO VDOHDQG WKHDVVHPEOLQJ LVGRQH
ZLWKDYLHZWRVXFKVDOHRUVXSSO\HLWKHUDWWKDWUHJLVWHUHGSKDUPDF\RU
DWDQ\RWKHU VXFKUHJLVWHUHGSKDUPDF\ IRUPLQJSDUWRI WKH VDPH UHWDLO
SKDUPDF\EXVLQHVVDQG
LL WKHPHGLFLQDOSURGXFWKDVQRWEHHQWKHVXEMHFWRIDQDGYHUWLVHPHQW
RUDQ\WKLQJGRQHE\RUXQGHUWKHVXSHUYLVLRQRIDSKDUPDFLVWZKLFKFRQVLVWVRI
SURFXULQJ WKH SUHSDUDWLRQ RU GLVSHQVLQJ RI D PHGLFLQDO SURGXFW LQ DFFRUGDQFH
ZLWK D SUHVFULSWLRQ JLYHQ E\ D SUDFWLWLRQHU RU RI SURFXULQJ WKH DVVHPEO\ RI D
PHGLFLQDOSURGXFW
1.4 *HQHUDOVDOHOLVWRU2YHU7KH&RXQWHU27&DQGSUHVFULSWLRQRQO\SURGXFWV
Sections 50 to 60 M A 1968 create a system of categories of medicinal products. There are
three primary categories:-
(a) *HQHUDOVDOHOLVWVRU27&SURGXFWV
These are the lower order medicinal products, which are specified as being
products which can with reasonable safety be sold or supplied without the need
for a pharmacist (Section 51).
The pharmacists role here is limited, as the products (e.g. headache pills, first aid
kits are by their nature regarded as sufficiently safe and straight forward as not to
require detailed personalised guidance. The pharmacists do not have a monopoly
over this category of products.
(b) 1RQJHQHUDOVDOHOLVWVSURGXFWVZKLFKDUHDOVRQRWSUHVFULSWLRQRQO\
These are the middle category medicinal products, which require the supervision
of a pharmacist at a registered pharmacy, but are still regarded as OTC products.
Here the pharmacist has the most important role, as the products have not been
prescribed, and the pharmacist must give advice on the appropriate product to use
and the correct dosage.
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(c) 3UHVFULSWLRQRQO\SURGXFWV
These are the most potentially dangerous products, which can only be distributed
by pharmacists in accordance with a prescription given by an appropriate
practitioner, for example by a doctor or dentist. (Within this category is a further
category of those prescription products which can only be distributed through
hospitals.)
The pharmacists role here is normally limited to ascertaining that a prescription is
required, advising on usage recommendations and reimbursement. The primary
responsibility, however, rests with the prescribing practitioner.
1.5 2WKHUUHJXODWLRQVRYHUSKDUPDFLVWV
Section 63 M A 1968 provides that it is an offence to add to or subtract anything from a
medicinal product.
Section 64 M A 1968 provides that it is an offence to sell any medicinal product which is
not of the nature or quality demanded.
Section 75 M A 1968 provides that pharmacists must submit details of the premises from
which a retail pharmacy business is being run.
Section 85 M A 1968 provides that it is an offence to describe any medicinal product
wrongly on a label or mark.
8. *(50$1<
The pharmacists’ monopoly is laid down in Section 43 of the “Law relating to the
Manufacture and Distribution of Pharmaceuticals” (“Arzneimittelgesetz-AMG”). According
to this provision, only qualified pharmacists are entitled to sell medical products falling
within the scope of the definition given by the AMG. In principle, the monopoly of
pharmacists affects both medical products which are subject to prescription and OTCs.
However, some OTC-products and some which are subject to prescription are excluded
from the pharmacists monopoly.
Regulations related to Pharmacists are laid down in the “Law on Pharmacies”
(“Apothekengesetz”). According to Section 1 pharmacists are obliged to provide for an
orderly supply of medical products in the interest of the general good. Any qualified
pharmacist must be ad personam authorised to run a pharmacy. The “Law on Pharmacies” is
based on the idea of the self-employed pharmacist running his own and only one pharmacy.
This provision is intended to guarantee that the pharmacist devotes all his efforts to one
pharmacy and feels personally responsible for his pharmacy in the public interest. As a
consequence, chains of pharmacies do not exist in Germany.
In 1994, the ban on the ownership of more than one pharmacy was modified to adjust
German legislation in line with the European law. Following the amendment of the “Law on
Pharmacies” individuals who are authorised by German law to run a pharmacy are now
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entitled to run one or several pharmacies in other Member States according to the Member
States’ relevant legislation. Conversely, pharmacists running one or several pharmacies in
one or more other Member States are entitled to run no more than one pharmacy in
Germany, in addition to the pharmacies run in other Member States on condition that the
respective Member States do not impose an obligation on the pharmacist to be present in his
pharmacy at all times. Apart from this amendment, the German legislator did not feel an
obligation to repeal the ban on the ownership of more than one pharmacy.
According to a decree dealing with the pharmacy business (“Apothekenbetriebsordnung”)
the pharmacist is, in principle, not entitled to sell anything other than medical products. As
a general rule, he may only sell anything other than medical products as far as it does not
affect the orderly operations of the pharmacy. Section 25 Apothekenbetriebsordnung
contains a list of products the pharmacist is entitled to offer for sale besides medical
products.
Pharmacists obtain their pharmaceutical supply either directly through the manufacturer or,
this is more common, through the wholesaler. However, to achieve a stronger bargaining
position in relation to manufacturers and wholesalers pharmacists have formed co-
operatives for the common purchase of medical products.
Pharmacists are not allowed to advertise or promote for their pharmacy.
9. ,7$/<
Under Italian Law, medicinal products -as defined in EU Directives- can only be purchased by final
consumers through pharmacies. This applies as well to the category of “SUHVLGL PHGLFR
FKLUXUJLFL” 25,  as well as to a number of OTC products and cosmetics.
Italian law provides for a number of provisions that are applicable to pharmacies and pharmacists.
Some of them are strictly inherent to the profession of pharmacies and to the exercise of
their activities. Other provisions apply directly to the marketing of pharmaceuticals.
As far as the first group of provisions is concerned, the profession of pharmacist can be carried out
only if the person satisfies a number of requirements and is duly registered with the
Pharmacists Society26. Pharmacists are subject to a number of duties.  Examples of
infringing behaviour are the grant of discounts to consumers or advertising of the
pharmacist’s activity.
10. %(/*,80
10.1 5HJXODWRU\IUDPHZRUN
24
 This section is up to date to 31 December 1997
25
 This category of pharmaceutical products includes both products for human beings (e.g. female hygiene products
could fall within) as well as for animals or even those for agricultural purposes. Some devices, such as surgeon
gloves, could also be “SUHVLGL”.
26
 The Pharmacist society is a body with administrative law relevance.
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The regulation of the profession of pharmacists in Belgium is similar to that in the UK.  The
profession of pharmacists is mainly governed by Royal Decree No. 78 of 10 November 1967
on the profession of doctors, nurses, paramedics and the medicinal commissions (the
’HFUHH). Pharmacists need to be member of a legally constituted professional
organisation for pharmacists (2UGH YDQ DSRWKHNHUV2UGUH GHV SKDUPDFLHQV).  This
organisation, LQWHU DOLD, supervises the good conduct of the profession and can impose
disciplinary and other measures set out in separate regulations.
- 28 -
10.2 /HJDOPRQRSRO\
Article 4 of the Decree grants pharmacists a monopoly for the provision of pharmacy services and the
sale of pharmaceutical products, as defined in the Decree. A university degree in pharmacy,
a certificate by the municipal commission and a registration on the list of the professional
organisation for pharmacists is required.  In addition, the opening of a pharmacy is subject to
a special permit issued by the Belgian Ministry of Public Heath.  The issuing of such a
permit depends on the density of  the population and the distance from other pharmacists in a
given area.
However, doctors can provide pharmaceutical products directly to their patients but only in urgent
circumstances.
Note that the Decree prohibits doctors to be pharmacists at the same time (Article 4bis).  Hence a
person who holds a degree in medicine and a degree in pharmacy cannot perform both
professions simultaneously.
10.3 ’XW\WRGHOLYHUDQGWKHULJKWWRVXEVWLWXWHIRUSKDUPDFLVWV
In principle a pharmacist is under a duty to deliver the product prescribed by a doctor and is not
entitled to substitute it with another product.  However the Decree provides for the
possibility to allow the pharmacists to substitute certain prescribed products with others
provided that the active ingredients are identical, the doctor has not explicitly prohibited the
possibility of substitution and the price of the substitute product is lower than the prescribed
one.
11. )5$1&(
The Public Health Code provides for a list of products which fall under the scope of the
pharmacy monopoly and which can, therefore only be distributed through pharmacies:
• the wholesale and retail of medicines;
• the preparation of medicines;
• the preparation and sale of medical dressings;
• the retail of essential oils;
• the retail of lacteal products for infants;
• the sale of medicinal herbs/plants
The retail of these products must be a direct sale, i.e. there must be no intermediary between
the pharmacy and the customer.
In case of breach of the pharmacy monopoly, the following sanctions apply :
• fine from FRF 3,600 up to FRF 18,000; and/or
• from 6 days to 6 months prison sentence.
- 29 -
12. ,PSDFW RI (FRPPHUFH RQ VLQJOH SKDUPDFLHV DQG JURXSV RI SKDUPDFLHV DQG VXSSO\
FKDLQ
The pharmacists as a result of the above legislation have been granted a significant monopoly in
dispensing medicinal products. This is a reflection of the importance attributed to their role
in ensuring the safety of consumers.
There has been a move in recent years in this field for pharmacies to be acquired by those above them
in the distribution chain from wholesalers to manufacturers. Chains of pharmacies are
particularly tempting for these acquisitions and therefore may be viewed as more vulnerable.
One of the primary benefits for the purchasing entity is that it gives direct access to the
consumers or patients, so that they can attempt to bring added value to the consumer. In
practise it seems likely that only the pharmacy chains would have sufficient resources in the
short term to invest in technology to facilitate e- commerce transactions on a large scale.
Within the existing legislative regime there will still be a need for pharmacists to supervise
distribution of non-general list products, although their role may change to an indirect
supervision via e-mail rather than through a traditional shop premises.
13. 5HJXODWLRQRIWKHDGYHUWLVLQJDQGSURPRWLRQRIPHGLFLQDOSURGXFWV
See Annex 4.
14. 5HJXODWLRQRIUHLPEXUVHPHQWIRUPHGLFLQDOSURGXFWV
See Annex 2.
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$11(;
3ULFHFRQWUROVDQGUHLPEXUVHPHQWRIPHGLFLQDOSURGXFWV
1. *HQHUDO
The market in medicinal products is strongly partitioned on the basis of price throughout Europe and
the world.  In addition to the normal competitive forces which cause price variation within
any product market, the price of pharmaceuticals is influenced by a number of direct and
indirect controls.
In most countries, there is some form of governmental intervention in the pricing of pharmaceutical
products.  In some cases, the control arises by virtue of the government (through its control
of the national health care system) or other healthcare provider in the jurisdiction which is
the principal purchaser of medicinal products.  Consequently it can maintain a strong
negotiating position and exert strong downwards pressure on prices.
Alternatively, the control of prices may be achieved through laws or regulations, including direct
control of prices for new and/or existing medicines on a product by product basis, indirect
price control by limiting reimbursement levels and generating a reference pricing system,
profit controls, and mandatory cuts or freezes in medicine prices generally.  It is the
differences in these systems which contribute to the maintenance of large price differentials
between countries.
Below is a table which summarises the techniques for regulating pharmaceutical prices employed by a
sample of different countries both within and outside the EU27.
27
 "International Transfer Pricing in the Ethical Pharmaceutical Industry", Maurice H Collins, IBFD Publications
BV.
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&RXQWU\ SULFHIL[LQJ UHVWULFWLRQVRQSUHVFULSWLRQ UHLPEXUVHPHQWUXOHV SURILWFRQWUROV
UK No direct fixing. Negative list excludes certain
pharmaceuticals (in particular
branded pharmaceuticals) from
reimbursement.
Patient pays a comparatively small flat fee
for each item on prescription (unless they
qualify for exemption).  Pharmacists are
reimbursed the excess cost of the
pharmaceutical (on condition that it is not
on the excluded list).
Under the Pharmaceutical Price
Regulation Scheme limits are
placed upon the overall
profitability of a given
pharmaceutical company (across
their product range), measured by
the rate of return on capital
employed, on sales of products
supplied under the National
Health Service.  The permitted
rate of return for a given company
is determined through
negotiations with the UK
Department of Health.  If a
company’s profits exceed its
agreed rate of return it must
negotiate either a repayment of
past profits or agree future price
reductions28.
France Prices have to be approved by the
Government Medicines Directorate
(which can take several years after a
market authorisation has been
granted).  Pricing approval depends
on factors such as the therapeutic
A prescription is required.
Reimbursement restricted to
pharmaceuticals which are
positively listed, i.e. the
medicine must feature on a list
of refundable medicines
The patient pays the full price for his
medication and then receives
reimbursement at one or other of a small
variety of rates related to the severity of
the disease.  Thus the 100 percent rate
applies to certain life-saving therapies, the
None
28
 The scheme is due to expire at the end of 1998 and negotiations are under way in relation to the form of the scheme which will replace it.
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&RXQWU\ SULFHIL[LQJ UHVWULFWLRQVRQSUHVFULSWLRQ UHLPEXUVHPHQWUXOHV SURILWFRQWUROV
advantage and improved efficacy of
the pharmaceutical and the research
effort underlying it.  Comparison is
made with the prices of a basket of
comparable products in the
therapeutic class.
established by order of the
Ministry of Health and the
Ministry of Social Security.
60 percent rate to the majority of
pharmaceuticals and the 30 percent rate to
pharmaceuticals treating minor disorders.
Germany Decree which lists authorised
medicines with a corresponding price
to which pharmacists are bound.
Negative list excludes certain
pharmaceuticals from
reimbursement, including
those:-
(a) whose effects are not
certain because of the
various active agents the
pharmaceutical contains,
(b) which do not contain
components essential for
achieving the therapy’s
objectives,
(c) whose therapeutic
effectiveness could not be
proved.
A reference price system operates.
Reimbursement is capped at a reference
level which is determined by the average
price of pharmaceuticals which:-
(a) are constituted of identical active
ingredients;
(b) are constituted of pharmacologically
and therapeutically comparable
active ingredients; and
(c) which operate in a pharmacologically
comparable manner.
The patient has to pay the difference
between the cost of the pharmaceutical
prescribed and the reimbursement level of
the reference pharmaceutical29.
None
29
 Patented pharmaceuticals which are truly innovative are excluded from the reference price system and patients pay a small flat prescription fee for them.
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&RXQWU\ SULFHIL[LQJ UHVWULFWLRQVRQSUHVFULSWLRQ UHLPEXUVHPHQWUXOHV SURILWFRQWUROV
Italy To be eligible for reimbursement the
price of the pharmaceutical must be
approved by the Government Pricing
Committee.  Therapeutic advantages
and production costs are all taken
into account.
A negative list excludes a
considerable number of
pharmaceuticals from
reimbursement.
The cost of most pharmaceuticals is only
partly reimbursed.  The patient pays a
small fixed prescription charge plus a co-
payment or ’ticket’.  The ticket is a
percentage of the price of the
pharmaceutical.  It varies according to the
product Class.  The pharmacist claims
reimbursement of the remainder.
None
Australia Price negotiations take place with the
Independent Pharmaceutical Benefit
Pricing Authority (PBPA).  In
determining the price the PBPA
takes into account, inter alia:-
(a) the level of activity of the
company in Australia;
(b) prices of comparative
therapeutic products; and
(c) manufacturers costs.
For products already on the list due
PBPA performs a biennial price
review taking the same factors into
account.
Positive list exists.  Costs of
pharmaceuticals are only
reimbursed if they are included
on a positive list under the
Pharmaceutical Benefits
Scheme (PBS).  The
Commonwealth Department of
Community Services  and
Health (DCSH) decides on
applications to have a product
included in the list on the basis
of recommendations made by
the Pharmaceutical Benefits
Advisory Committee.
A co-payment from the patient is
generally required which varies according
to the category of the patient.  A reference
pricing system also operates.  It sets a
minimum price for a pharmaceutical
product where competing brands are
available.  The level of reimbursement is
based on the price negotiated for the
cheapest brand (the "bench-mark").
Patients have to pay the difference
between the price of a pharmaceutical and
the bench-mark.
None
Japan Prices are set by the Special None Patients pay a proportion of the full cost None
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&RXQWU\ SULFHIL[LQJ UHVWULFWLRQVRQSUHVFULSWLRQ UHLPEXUVHPHQWUXOHV SURILWFRQWUROV
Committee on Drug Prices.  Prices
for all pharmaceuticals are included
in the official pharmacopeia or
registry of pharmaceuticals approved
for use in Japan.  The price is set by
comparison with the approved price
for a pharmaceutical with similar
properties (efficacy, structural
formula, pharmacological action etc)
already listed by the Ministry or,
where there is no such
pharmaceutical, by reference to the
cost of manufacture.  After two years
on the market the price of the
pharmaceutical can be revised
downwards.
of a prescription pharmaceutical, the rest
is reimbursed.
United
States
No controls. None There are limits to the prices which
authorities will pay for pharmaceuticals
prescribed for Medicaid patients (covers
only 10 to 15 percent by value of the US
domestic pharmaceutical market).  Under
US legislation those pharmaceuticals must
be sold to Medicaid administrations at a
discount from the wholesale price.  The
maximum discount represents the
difference between the average selling
price paid to the manufacturers and the
lowest price paid by any US company.
None
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&RXQWU\ SULFHIL[LQJ UHVWULFWLRQVRQSUHVFULSWLRQ UHLPEXUVHPHQWUXOHV SURILWFRQWUROV
Other (non Medicaid) patients pay the full
cost of their medicines, subject to private
insurance cover in some cases.
Belgium The Belgian Minister of Economic
Affairs is the competent body for the
approval of prices for pharmaceutical
products.  Prices for products on
prescription have to be approved
within 90 days and for OTC products
within 60 days after the application.
Pricing approval depends LQWHUDOLD
on a consultation with the
Commission for the Pricing of
Pharmaceutical Products
(3ULM]HQFRPPLVVLHYRRUGH
)DUPDFHXWLVFKH6SHFLDOLWHLWHQOD
&RPPLVVLRQGHV3UL[GHV6SpFLDOLWpV
3KDUPDFHXWLTXHV market conditions
and pricing in other EU Member
States.
Reimbursement restricted to
pharmaceuticals which are
positively listed
The patient pays the full price for his
medication and then receives full or
partial reimbursement depending on the
type of pharmaceutical
None
- 36 -
2. 7KHSUREOHPVZLWK,QWHUQHWWUDGLQJ
Price differentials present a number of problems for pharmaceutical trading on the Internet.  On the
commercial front, Internet trading makes price differentials much more transparent,
potentially increasing the opportunities and incentives for parallel trading - already a
significant concern for the pharmaceutical industry.
In theory, suppliers could be forced to vary the price of the product on offer depending on the
location of the customer who has accessed their web-site.  If they fail to observe national
pricing restrictions the supplier may be subjected to scrutiny and prosecution by the national
bodies responsible for policing the pricing system.
Alternatively, the relevant authorities may take the view that the supplier is free to price products on
their web-site according to the pricing restrictions in the territory in which the server is
located.  This would enable suppliers with web-sites in, for instance, the US where there are
no (or very few) restrictions on pricing to offer pharmaceuticals for sale at whatever prices
they choose and can commercially maintain.  This is subject to the problems caused by
national reimbursement systems.
3. 5HLPEXUVHPHQW
Taking the example above, the freedom of the supplier to set its prices may operate smoothly if the
consumer is personally funding the purchase.  However, the supplier’s freedom may be
academic if the consumer is seeking to take advantage of the reimbursement system operated
by the national health care provider in the territory in which the consumer is located.
There are two scenarios: the first in which the consumer is responsible for obtaining reimbursement,
(for example the French system); and the second in which the supplier is responsible for
obtaining reimbursement from the health care provider (as in the UK for example).  In the
first situation, the consumer will not purchase the product on the Internet from a territory
outside that in which they are located unless they are confident that they will ultimately be
able to obtain reimbursement.  In the latter situation, the supplier will not dispense products
to the consumer unless it can be confident it will be able to recover the full price of the
product and that the administrative burden of doing so will not be so great as to negate its
profit.
In the EU, where approximately 65% of the pharmaceutical market (by value) is accounted for by
products that are reimbursed, this hurdle could prove to be insurmountable resulting in
Internet trade being restricted in the EU to a grey market in which the patient pays the full
price of product.  Two recent ECJ decisions, however, have a bearing on how
pharmaceutical Internet trade develops in the EU.
The two decisions30 concern the reimbursement of Luxembourg citizens for medical costs which they
incurred abroad.  In the first case, the patient had purchased a pair of spectacles from an
optician established in Belgium on a prescription from an ophthalmologist established in
30
 1LFRODV’HFNHUY&DLVVHGH0DODGLHGHV(PSOR\pV3ULYpV(28 April 1998, Case C-120/95) and 5D\PRQG.RKOO
Y8QLRQGHV&DLVVHVGH0DODGLH, (28 April 1998, Case C-158/96).
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Luxembourg and sought to recover the cost from the Luxembourg Sick Fund.  In the second
case, the patient sought authorisation from the Sick Fund to receive treatment from an
orthodentist established in Germany.  In both cases the Luxembourg health care provider
refused to reimburse the cost of the treatment on the basis that it had been or was to be
purchased abroad and, in the first case, on the basis that prior authorisation for the purchase
had not been maintained.
The ECJ decision centred on whether the national legislation permitting the health care providers to
refuse reimbursement was consistent with Article 30 and 36 of the EC Treaty, or whether
such provisions fall outside the scope of these articles in that they concern social security
issues.  In finding that the provisions do not escape the effect of Article 30 merely because
they fall within the sphere of social security, the ECJ acknowledged that Member States are
entitled to establish their own reimbursement systems, but held that they must nevertheless
comply with Community law when exercising their powers under these systems.
On the facts, the ECJ held that the provisions are capable of hindering intra-community trade and the
Court therefore upheld the right of every citizen to obtain goods and services relating to
medical care and treatment from whichever Member State they choose.
The above decision is unlikely to be extended to purchases outside the EU, particularly if the
principles established in the Silhouette case31 are applied by analogy.  Consequently the
above decisions are only likely to be helpful in relation to intra European Internet trade and
not trade with, for example, the US.
31
 6LOKRXHWWH,QWHUQDWLRQDO6FKPLHG*PE+	&R.*Y+DUWODXHU+DQGHVJHVHOOVFKDIWPE+ (16 July 1998, case
C-355/96)
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$11(;
5HJXODWRU\,VVXHV
1. %DFNJURXQG
World-wide regulation by Government Authorities has a significant effect on the
development, production, marketing, labelling and reimbursement of medicinal products
and devices, regulating, inter alia, the placing on the market of medicinal products and
medical devices (marketing authorisations), product testing (pre-clinical and clinical trials),
and classification, labelling and advertising of medicines.
Any analysis of E-commerce and the pharmaceutical industry must take account of the
current regulatory framework within which the pharmaceutical industry is required to
operate.  Whilst this paper concentrates on European issues, the world wide nature of the
Internet necessitates an awareness of how Europe sits within the world-wide pharmaceutical
regulatory regime and the regulatory issues which arise from the world-wide nature of E-
commerce.
2. (XURSHDQ8QLRQ
The regulation of medicinal products and devices in Europe is determined at Community
level by Directives which are implemented in each Member State by national laws and
enforced at a national level by national agencies (for example the Medicines Control
Agency in the UK and the Geneesmiddelencommisie, Commission des Médicaments in
Belgium).  Brief details of the Directives which are of primary relevance from an E-
commerce perspective are set out below:
2.1 0DUNHWLQJ $XWKRULVDWLRQV IRU PHGLFLQDO SURGXFWV &RXQFLO ’LUHFWLYH  ((& RI 
-DQXDU\  RQ WKH DSSUR[LPDWLRQ RI SURYLVLRQV ODLG GRZQ E\ ODZ UHJXODWLRQ RU
DGPLQLVWUDWLYHDFWLRQUHODWLQJWRSURSULHWDU\PHGLFLQDOSURGXFWV
This Directive sets out the general principle that any medicinal product must have a
marketing authorisation before it can be placed on the market in the European Union
(Article 3).  Medicinal products are defined in Article 2 as being:-
$Q\VXEVWDQFHRUFRPELQDWLRQRIVXEVWDQFHVSUHVHQWHGIRUWUHDWLQJRUSUHYHQWLQJ
GLVHDVHLQKXPDQEHLQJVRUDQLPDOV$Q\VXEVWDQFHRUFRPELQDWLRQRIVXEVWDQFHV
ZKLFKPD\EHDGPLQLVWHUHGWRKXPDQEHLQJVRUDQLPDOVZLWKDYLHZWRPDNLQJD
PHGLFDOGLDJQRVLVRUWRUHVWRULQJFRUUHFWLQJRUPRGLI\LQJSK\VLRORJLFDOIXQFWLRQV
LQ KXPDQV EHLQJV RU LQ DQLPDOV LV OLNHZLVH FRQVLGHUHG D PHGLFLQDO SURGXFW
ZKHUH
VXEVWDQFH
PHDQV
DQ\PDWWHU LUUHVSHFWLYHRIRULJLQZKLFKPD\EHKXPDQHJKXPDQEORRGDQG
KXPDQ EORRG SURGXFWV DQLPDO HJ PLFURRUJDQLVPV ZKROH DQLPDOV SDUWV RI
RUJDQV DQLPDO VHFUHWLRQV WR[LQV H[WUDFWV EORRG  SURGXFWV HWF YHJHWDEOH HJ
PLFURRUJDQLVPV SODQWV SDUWV RI SODQWV YHJHWDEOH VHFUHWLRQV H[WUDFWV HWF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FKHPLFDO HJ HOHPHQWV QDWXUDOO\ RFFXUULQJ FKHPLFDO PDWHULDOV DQG FKHPLFDO
SURGXFWVREWDLQHGE\FKHPLFDOFKDQJHRUV\QWKHVLV
Prior to 1 January 1998, national marketing authorisation applications could be made
concurrently to each member state.  This system has now been totally replaced by the
"Mutual Recognition System" and the "Centralised System" for obtaining European
marketing authorisations.  With effect from 1 January 1995, the European Agency for the
Evaluation of Medicinal Products ("EMEA") has taken responsibility for the co-ordination
of scientific resources within the EU, with a view to evaluating and supervising medicinal
products for human and veterinary use across the EU.  On the basis of the EMEA’s opinion,
the European Commission authorises the marketing of a product approved by the
Centralised System and arbitrates between member states on other applications submitted
via the Mutual Recognition System.
(a) 7KH&HQWUDOLVHG6\VWHP
The Centralised System is compulsory for certain biotechnology products, and
optional for certain other medicinal products, including new active substances not
previously authorised in the European Union, products administered by innovative
and novel delivery systems and significant new indications for existing products.  The
EMEA co-ordinates the registration process.  However, the CPMP, a body of
scientific experts drawn from each Member State, undertakes the scientific
assessment of each product dossier and gives an opinion as to whether the product
meets the criteria for authorisation.  Time periods are laid down for various stages in
the approval process, including allowances for questions and appeals.  The decision
to grant or refuse a marketing authorisation is taken by the Commission and, when
granted, the single marketing authorisation obtained is valid throughout all Member
States and the European Free Trade Association.
(b) 7KH0XWXDO5HFRJQLWLRQ6\VWHP
The Mutual Recognition System is based upon a marketing authorisation granted by
one national regulatory authority, the "Reference Member State" or "RMS".  Having
obtained a marketing authorisation from the RMS, the authorisation holder may apply
to the regulatory authorities of other Member States to "recognise" that prior
authorisation and to issue national marketing authorisations on the same terms.  Such
applications can be made sequentially.  There are procedures and time limits
according to which objections by member states can be raised and appeals may be
heard, which can significantly lengthen the time from initial application to approval.
Arbitrations are handled by the CPMP whose decision, when adopted by the
Commission, is binding on all Member States.
Marketing authorisations are generally granted for a five year period and are renewable for
five-year periods thereafter.  Regulatory authorities will continue to supervise a
pharmaceutical once it has been placed on the market and they generally have the power to
vary, suspend or revoke a marketing authorisation at any time if they are no longer satisfied
as to the product’s safety, quality or efficacy.  There is a continuing obligation on the holder
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of the authorisation to study adverse events to the relevant authorities and to keep the safety
of products under review.
2.2 0HGLFDO’HYLFHV((&
This Directive provides that any medical device must be "CE" marked, following which it
may be sold freely anywhere in the European economic area without further control.
In order to affix the CE mark to a device, a manufacturer must declare conformity of the
product with the provisions of the Directive, including the "essential requirements".  The
essential requirements with which the product must comply depend upon the classification
of the device in question.  Devices are classified into one of four categories: I (low risk), IIa
and IIb (both intermediate) and III (high risk).  The system is intended to be self-regulating,
with manufacturers themselves deciding into which class their products fall.  For certain
Class I devices, the manufacturers themselves may declare conformity with the provisions
of the directive.  Other classes require the involvement of a Notified Body, a certification
organisation appointed to ensure that the appropriate assessment procedures have been
followed by manufacturers of medical devices.  In each member state, Notified Bodies are
designated by the competent authority in that territory which is the body which acts on
behalf of the Government of the relevant member state, to enforce the requirements of the
directive.  In the UK, the Secretary of State for Health has delegated the running of this
process to the Medical Devices Agency.
The following two Directives, containing broadly equivalent requirements, govern the
marketing of active implantable devices (such as heart pacemakers) and invitro diagnostic
products.
2.3 &ODVVLILFDWLRQRI+XPDQDQG3UHVFULSWLRQ2QO\0HGLFLQHV&RXQFLO’LUHFWLYH((&
RI0DUFKFRQFHUQLQJWKHFODVVLILFDWLRQIRUWKHVXSSO\RIPHGLFLQDOSURGXFWVIRU
KXPDQXVH
This Directive contains provisions which classify the supply of medicinal products for
human use in the Community into those which are subject to medicinal prescription and
those which are not.  The relevant guidelines are set out in Article 3 as follows:-
(i) 0HGLFLQDOSURGXFWVVKDOOEHVXEMHFWWRPHGLFDOSUHVFULSWLRQZKHUHWKH\
• DUHOLNHO\WRSUHVHQWDGDQJHUHLWKHUGLUHFWO\RULQGLUHFWO\HYHQZKHQXVHG
FRUUHFWO\LIXWLOLVHGZLWKRXWPHGLFDOVXSHUYLVLRQRU
• DUHIUHTXHQWO\DQGWRDYHU\ZLGHH[WHQWXVHGLQFRUUHFWO\DQGDVDUHVXOW
DUHOLNHO\WRSUHVHQWDGLUHFWRULQGLUHFWGDQJHUWRKXPDQKHDOWKRU
• FRQWDLQVXEVWDQFHVRUSUHSDUDWLRQVWKHUHRIWKHDFWLYLW\DQGRUVLGHHIIHFWV
RIZKLFKUHTXLUHIXUWKHULQYHVWLJDWLRQRU
• DUHQRUPDOO\SUHVFULEHGE\DGRFWRUWREHDGPLQLVWHUHGSDUHQWDOO\
(ii) :KHUH 0HPEHU 6WDWHV SURYLGH IRU WKH VXEFDWHJRU\ RI PHGLFLQDO SURGXFWV
VXEMHFW WR VSHFLDO PHGLFDO SUHVFULSWLRQ WKH\ VKDOO WDNH DFFRXQW RI WKH
IROORZLQJIDFWRUV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• WKH PHGLFLQDO SURGXFW FRQWDLQV LQ D QRQH[HPSW TXDQWLW\ D VXEVWDQFH
FODVVLILHGDVDQDUFRWLFRUDSV\FKRWURSLFVXEVWDQFHZLWKLQWKHPHDQLQJRI
WKH LQWHUQDWLRQDO FRQYHQWLRQV LQ IRUFH 8QLWHG 1DWLRQV &RQYHQWLRQV RI
DQGRU
• WKHPHGLFLQDOSURGXFWLVOLNHO\LILQFRUUHFWO\XVHGWRSUHVHQWDVXEVWDQWLDO
ULVN RI PHGLFLQDO DEXVH WR OHDG WR DGGLFWLRQ RU EH PLVXVHG IRU LOOHJDO
SXUSRVHVRU
• WKHPHGLFLQDOSURGXFWFRQWDLQVDVXEVWDQFHZKLFKE\UHDVRQRILWVQRYHOW\
RU SURSHUWLHV FRXOG EH FRQVLGHUHG DV EHORQJLQJ WR WKDW JURXS DV D
SUHFDXWLRQDU\PHDVXUH
(iii) :KHUH 0HPEHU 6WDWHV SURYLGH IRU WKH VXEFDWHJRU\ RI PHGLFLQDO SURGXFWV
VXEMHFW WR UHVWULFWHG SUHVFULSWLRQ WKH\ VKDOO WDNH DFFRXQW RI WKH IROORZLQJ
IDFWRUV
• WKH PHGLFLQDO SURGXFW EHFDXVH RI LWV SKDUPDFHXWLFDO FKDUDFWHULVWLFV RU
QRYHOW\ RU LQ WKH LQWHUHVWV RI SXEOLF KHDOWK LV UHVHUYHG IRU WUHDWPHQWV
ZKLFKFDQRQO\EHIROORZHGLQDKRVSLWDOHQYLURQPHQW
• WKHPHGLFLQDOSURGXFWLVXVHGLQWKHWUHDWPHQWRIFRQGLWLRQVZKLFKPXVWEH
GLDJQRVHG LQ D KRVSLWDO HQYLURQPHQW RU LQVWLWXWLRQV ZLWK DGHTXDWH
GLDJQRVWLF IDFLOLWLHV DOWKRXJK DGPLQLVWUDWLRQ DQG IROORZXS PD\ EH
FDUULHGRXWHOVHZKHUHRU
• WKHPHGLFLQDOSURGXFWLVLQWHQGHGIRURXWSDWLHQWVEXWLWVXVHPD\SURGXFH
YHU\VHULRXVVLGHHIIHFWVUHTXLULQJDSUHVFULSWLRQGUDZQXSDVUHTXLUHGE\
DVSHFLDOLVWDQGVSHFLDOVXSHUYLVLRQWKURXJKRXWWKHWUHDWPHQW
(iv) $FRPSHWHQWDXWKRULW\PD\ZDLYHDSSOLFDWLRQRISDUDJUDSKVLLLDQGLLL
KDYLQJUHJDUGWR
• WKH PD[LPXP VLQJOH GRHV WKH PD[LPXP GDLO\ GRVH WKH VWUHQJWK WKH
SKDUPDFHXWLFDOIRUPFHUWDLQW\SHVRISDFNDJLQJDQGRU
• RWKHUFLUFXPVWDQFHVRIXVHZKLFKLWKDVVSHFLILHG
(v) ,I D FRPSHWHQW DXWKRULW\ GRHV QRW GHVLJQDWH PHGLFLQDO SURGXFWV LQWR VXE
FDWHJRULHVUHIHUUHGWR LQ$UWLFOH LWVKDOOQHYHUWKHOHVV WDNH LQWRDFFRXQW
WKHFULWHULDUHIHUUHGWR LQSDUDJUDSKVDQGRI WKLV$UWLFOH LQGHWHUPLQLQJ
ZKHWKHU DQ\ PHGLFLQDO SURGXFW VKDOO EH FODVVLILHG DV D SUHVFULSWLRQRQO\
PHGLFLQH
2.4 /HDIOHWLQJDQG/DEHOOLQJ&RXQFLO’LUHFWLYH((&RI0DUFKRQWKHODEHOOLQJ
RIPHGLFLQDOSURGXFWVIRUKXPDQXVHDQGRQSDFNDJHOHDIOHWV
This Directive sets out the requirements for the labelling of medicinal products for human
use and the content of leaflets inserted in the packages of such products.  The Directive, at
Article 2, sets out detailed requirements for the labelling of the outer or immediate
packaging of medicinal products.  These requirements are:-
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(i) WKHQDPHRIWKHPHGLFLQDOSURGXFW IROORZHGE\WKHFRPPRQQDPHZKHUH WKH
SURGXFW FRQWDLQV RQO\ RQH DFWLYH LQJUHGLHQW DQG LI LWV QDPH LV DQ LQYHQWHG
QDPH ZKHUH D PHGLFLQDO SURGXFW LV DYDLODEOH LQ VHYHUDO SKDUPDFHXWLFDO
IRUPVDQGRUVHYHUDOVWUHQJWKVWKHSKDUPDFHXWLFDOIRUPDQGRUWKHVWUHQJWK
EDE\ FKLOG RU DGXOW DV DSSURSULDWH PXVW EH LQFOXGH LQ WKH QDPH RI WKH
PHGLFLQDOSURGXFW
(ii) D VWDWHPHQW RI WKH DFWLYH LQJUHGLHQWV H[SUHVVHG TXDOLWDWLYHO\ DQG
TXDQWLWDWLYHO\SHUGRVDJHXQLWRUDFFRUGLQJWRWKHIRUPRIDGPLQLVWUDWLRQIRU
DJLYHQYROXPHRUZHLJKWXVLQJWKHLUFRPPRQQDPHV
(iii) WKHSKDUPDFHXWLFDOIRUPDQGWKHFRQWHQWVE\ZHLJKWE\YROXPHRUE\QXPEHU
RIGRVHVRIWKHSURGXFW
(iv) D OLVW RI WKRVH H[FLSLHQWV NQRZQ WR KDYH D UHFRJQLVHG DFWLRQ RU HIIHFW DQG
LQFOXGHGLQWKHJXLGHOLQHVSXEOLVKHGSXUVXDQWWR$UWLFOH +RZHYHULI WKH
SURGXFWLVLQMHFWDEOHRUDWRSLFDORUH\HSUHSDUDWLRQDOOH[FLSLHQWVPXVWEH
VWDWHG
(v) WKHPHWKRGDQGLIQHFHVVDU\WKHURXWHRIDGPLQLVWUDWLRQ
(vi) DVSHFLDOZDUQLQJWKDWWKHPHGLFLQDOSURGXFWPXVWEHVWRUHGRXWRIUHDFKRI
FKLOGUHQ
(vii) DVSHFLDOZDUQLQJLIWKLVLVQHFHVVDU\IRUWKHPHGLFLQDOSURGXFWFRQFHUQHG
(viii) WKHH[SLU\GDWHLQFOHDUWHUPVPRQWK\HDU
(ix) VSHFLDOVWRUDJHSUHFDXWLRQVLIDQ\
(x) VSHFLDO SUHFDXWLRQV IRU GLVSRVDO RI XQXVHG PHGLFLQDO SURGXFWV RU ZDVWH
PDWHULDOVGHULYHGIURPVXFKSURGXFWVLIDSSURSULDWH
(xi) WKH QDPH DQG DGGUHVV RI WKH KROGHU RI WKH DXWKRULVDWLRQ IRU SODFLQJ WKH
PHGLFLQDOSURGXFWRQWKHPDUNHW
(xii) WKH QXPEHU RI WKH DXWKRULVDWLRQ IRU SODFLQJ WKH PHGLFLQDO SURGXFW RQ WKH
PDUNHW
(xiii) WKHPDQXIDFWXUHU
VEDWFKQXPEHU
(xiv) LQ WKH FDVH RI VHOIPHGLFDWLRQ LQVWUXFWLRQV RQ WKH XVH RI WKH PHGLFLQDO
SURGXFWV
Article 7 of the Directive provides that the packaging leaflets must include the following
information in the following order:-
(xv) IRUWKHLGHQWLILFDWLRQRIWKHPHGLFLQDOSURGXFW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• WKHQDPHRI WKHPHGLFLQDOSURGXFW IROORZHGE\ WKHFRPPRQQDPH LI WKH
SURGXFWFRQWDLQVRQO\RQHDFWLYHLQJUHGLHQWDQGLILWVQDPHLVDQLQYHQWHG
QDPHZKHUHDPHGLFLQDOSURGXFW LVDYDLODEOH LQ VHYHUDOSKDUPDFHXWLFDO
IRUPV DQGRU VHYHUDO VWUHQJWKV WKH SKDUPDFHXWLFDO IRUP DQGRU WKH
VWUHQJWKIRUH[DPSOHEDE\FKLOGDGXOWPXVWEHLQFOXGHGLQWKHQDPHRI
WKHPHGLFLQDOSURGXFW
• D IXOO VWDWHPHQW RI WKH DFWLYH LQJUHGLHQWV DQG H[FLSLHQWV H[SUHVVHG
TXDOLWDWLYHO\ DQG D VWDWHPHQW RI WKH DFWLYH LQJUHGLHQWV H[SUHVVHG
TXDQWLWDWLYHO\XVLQJWKHLUFRPPRQQDPHVLQWKHFDVHRIHDFKSUHVHQWDWLRQ
RIWKHSURGXFW
• WKH SKDUPDFHXWLFDO IRUP DQG WKH FRQWHQWV E\ ZHLJKW E\ YROXPH RU E\
QXPEHU RI GRVHV RI WKH SURGXFW LQ WKH FDVH RI HDFK SUHVHQWDWLRQ RI WKH
SURGXFW
• WKH SKDUPDFRWKHUDSHXWLF JURXS RU W\SH RI DFWLYLW\ LQ WHUPV HDVLO\
FRPSUHKHQVLEOHIRUWKHSDWLHQW
• WKH QDPH DQG DGGUHVV RI WKH KROGHU RI WKH DXWKRULVDWLRQ IRU SODFLQJ WKH
PHGLFLQDOSURGXFWRQWKHPDUNHWDQGRIWKHPDQXIDFWXUHU
(xvi) WKHWKHUDSHXWLFLQGLFDWLRQV
(xvii) DOLVWRILQIRUPDWLRQZKLFKLVQHFHVVDU\EHIRUHWDNLQJWKHPHGLFLQDOSURGXFW
• FRQWUDLQGLFDWLRQV
• DSSURSULDWHSUHFDXWLRQVIRUXVH
• IRUPV RI LQWHUDFWLRQ ZLWK RWKHU PHGLFLQDO SURGXFWV DQG RWKHU IRUPV RI
LQWHUDFWLRQ IRU H[DPSOH DOFRKRO WREDFFR IRRGVWXIIV ZKLFK PD\ DIIHFW
WKHDFWLRQRIWKHPHGLFLQDOSURGXFW
• VSHFLDOZDUQLQJV
WKLVOLVWPXVW
• WDNH LQWR DFFRXQW WKH SDUWLFXODU FRQGLWLRQ RI FHUWDLQ FDWHJRULHV RI XVHUV
HJFKLOGUHQSUHJQDQWRUEUHDVWIHHGLQJZRPHQWKHHOGHUO\SHUVRQVZLWK
VSHFLILFSDWKRORJLFDOFRQGLWLRQV
• PHQWLRQLIDSSURSULDWHSRWHQWLDOHIIHFWVRQWKHDELOLW\WRGULYHYHKLFOHVRU
WRRSHUDWHPDFKLQHU\
• GHWDLO WKRVHH[FLSLHQWVNQRZOHGJHRIZKLFKLV LPSRUWDQW IRU WKHVDIHDQG
HIIHFWLYH XVH RI WKH PHGLFLQDO SURGXFW DQG LQFOXGHG LQ WKH JXLGHOLQHV
SXEOLVKHGSXUVXDQWWR$UWLFOH
(xviii) WKHQHFHVVDU\DQGXVXDOLQVWUXFWLRQVIRUSURSHUXVHLQSDUWLFXODU
• WKHGRVDJH
• WKHPHWKRGDQGLIQHFHVVDU\URXWHRIDGPLQLVWUDWLRQ
• WKH IUHTXHQF\ RI DGPLQLVWUDWLRQ VSHFLI\LQJ LI QHFHVVDU\ WKH DSSURSULDWH
WLPHDWZKLFKWKHPHGLFLQDOSURGXFWPD\RUPXVWEHDGPLQLVWHUHG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DQGDVDSSURSULDWHGHSHQGLQJRQWKHQDWXUHRIWKHSURGXFW
• WKHGXUDWLRQRIWUHDWPHQWZKHUHLWVKRXOGEHOLPLWHG
• WKHDFWLRQWREHWDNHQLQWKHFDVHRIDQRYHUGRVHIRUH[DPSOHV\PSWRPV
HPHUJHQF\SURFHGXUHV
• WKHFRXUVHRIDFWLRQWRWDNHZKHQRQHRUPRUHGRHVKDYHQRWEHHQWDNHQ
• LQGLFDWLRQLIQHFHVVDU\RIWKHULVNRIZLWKGUDZDOHIIHFWV
(xix) DGHVFULSWLRQRIWKHXQGHVLUDEOHHIIHFWVZKLFKFDQRFFXUXQGHUQRUPDOXVHRI
WKHPHGLFLQDOSURGXFWDQGLIQHFHVVDU\WKHDFWLRQWREHWDNHQLQVXFKDFDVH
WKHSDWLHQWVKRXOGEHH[SUHVVO\LQYLWHGWRFRPPXQLFDWHDQ\XQGHVLUDEOHHIIHFW
ZKLFKLVQRWPHQWLRQHGLQWKHOHDIOHWWRKLVGRFWRURUWRKLVSKDUPDFLVW
(xx) DUHIHUHQFHWRWKHH[SLU\GDWHLQGLFDWHGRQWKHODEHOZLWK
• DZDUQLQJDJDLQVWXVLQJWKHSURGXFWDIWHUWKLVGDWH
• ZKHUHDSSURSULDWHVSHFLDOVWRUDJHSUHFDXWLRQV
• LIQHFHVVDU\DZDUQLQJDJDLQVWFHUWDLQYLVLEOHVLJQVRIGHWHULRUDWLRQ
(xxi) WKHGDWHRQZKLFKWKHSDFNDJHOHDIOHWZDVODVWUHYLVHG
Packaging and leaflet information must be in the official language or languages of the
Member State where the product is placed on the market (Article 4, Clause 2 and Article 8).
2.5 $GYHUWLVLQJ  &RXQFLO ’LUHFWLYH ((& RI  0DUFK  RQ WKH DGYHUWLVLQJ RI
PHGLFLQDOSURGXFWVIRUKXPDQXVH
This Directive sets out several important provisions which regulate the advertising of medicinal
products.  These are:-
(i) Article 2, Clause 1 provides that 0HPEHU 6WDWHV VKDOO SURKLELW DQ\
DGYHUWLVLQJ RI D PHGLFLQDO SURGXFW LQ UHVSHFW RI ZKLFK D PDUNHWLQJ
DXWKRULVDWLRQKDVQRWEHHQJUDQWHG
(ii) Article 2, Clause 3 provides that 
WKH DGYHUWLVLQJ RI D PHGLFLQDO SURGXFW 
VKDOO HQFRXUDJH WKH UDWLRQDO XVH RI WKHPHGLFLQDO SURGXFW E\ SUHVHQWLQJ LW
REMHFWLYHO\DQGZLWKRXWH[DJJHUDWLQJLWVSURSHUWLHVVKDOOQRWEHPLVOHDGLQJ

(iii) Article 3 provides
0HPEHU6WDWHVVKDOOSURKLELWWKHDGYHUWLVLQJWRWKHJHQHUDOSXEOLFRIPHGLFLQDOSURGXFWV
ZKLFK
• DUHDYDLODEOHRQPHGLFDOSUHVFULSWLRQRQO\ LQDFFRUGDQFHZLWK’LUHFWLYH
((&
• FRQWDLQ SV\FKRWURSLF RU QDUFRWLF VXEVWDQFH ZLWKLQ WKH PHDQLQJ RI WKH
LQWHUQDWLRQDOFRQYHQWLRQV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• PD\QRWEHDGYHUWLVHGWRWKHJHQHUDOSXEOLFLQDFFRUGDQFHZLWKSDUDJUDSK

0HGLFLQDO SURGXFWVPD\ EH DGYHUWLVHG WR WKH JHQHUDO SXEOLFZKLFK E\
YLUWXHRI WKHLUFRPSRVLWLRQDQGSXUSRVHDUH LQWHQGHGDQGGHVLJQHG IRUXVH
ZLWKRXW WKH LQWHUYHQWLRQRI DPHGLFDO GRFWRU IRU GLDJQRVWLF SXUSRVHV RI IRU
WKH SUHVFULSWLRQ RU PRQLWRULQJ RI WUHDWPHQW ZLWK WKH DGYLFH RI WKH
SKDUPDFLVWVLIQHFHVVDU\
Please refer to Annex 4 for further information on the regulation of the Advertising and
promotion of medicinal products.
2.6 7KH’LVWDQFH6HOOLQJ’LUHFWLYH’LUHFWLYH(&RIWKH(XURSHDQ3DUOLDPHQWDQGRIWKH
&RXQFLORI0D\RQWKHSURWHFWLRQRIFRQVXPHUVLQUHVSHFWRIGLVWDQFHFRQWUDFWV
The object of this Directive is, according to Article 1WRDSSUR[LPDWHWKHODZVUHJXODWLRQV
DQGDGPLQLVWUDWLYHSURYLVLRQVRIWKH0HPEHU6WDWHVFRQFHUQLQJGLVWDQFHFRQWUDFWVEHWZHHQ
FRQVXPHUVDQGVXSSOLHUVwhere ’distance contract’, means
DQ\FRQWUDFWFRQFHUQLQJJRRGVRUVHUYLFHVFRQFOXGHGEHWZHHQDVXSSOLHUDQGD
FRQVXPHUXQGHUDQRUJDQLVHGGLVWDQFHVDOHVRUVHUYLFHSURYLVLRQVFKHPHUXQE\
WKHVXSSOLHUZKRIRUWKHSXUSRVHRIWKHFRQWUDFWPDNHVH[FOXVLYHXVHRIRQHRU
PRUHUHDVRQVRIGLVWDQFHFRPPXQLFDWLRQXSWRDQGLQFOXGLQJWKHPRPHQWDWZKLFK
WKHFRQWUDFWLVFRQFOXGHG
The Directive includes a specific reference to medicinal products at Article 14, which
states:-
0HPEHU6WDWHVPD\LQWURGXFHRUPDLQWDLQLQWKHDUHDFRYHUHGE\WKLV’LUHFWLYH
PRUHVWULQJHQWSURYLVLRQVFRPSDWLEOHZLWKWKH7UHDW\WRHQVXUHDKLJKHUOHYHORI
FRQVXPHUSURWHFWLRQ6XFKSURYLVLRQVVKDOOZKHUHDSSURSULDWHLQFOXGHDEDQLQ
WKHJHQHUDO LQWHUHVWRQ WKHPDUNHWLQJRI FHUWDLQJRRGVRU VHUYLFHV SDUWLFXODUO\
PHGLFLQDOSURGXFWVZLWKLQWKHLUWHUULWRU\E\PHDQVRIGLVWDQFHFRQWUDFWVZLWKGXH
UHJDUGIRUWKH7UHDW\
2.7 6HOI5HJXODWLRQ2WKHU/HJLVODWLRQ
The above Directives are supported by national provisions, self regulation through codes of
ethics and practice and the general restriction to pharmacies of the supply of medicines to
the public.  Please refer to Annex 1 (regulation of registered pharmaceutical chemists) and 4
(Regulation of the Advertising and promotion of medicinal products) for further details.
3. 7+(81,7(’67$7(6
3.1 *HQHUDO
The problems which are posed by the application of the EU regulatory regime to E-commerce are
probably best illustrated by highlighting the current differences between the EU regulatory
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regime and the regulatory regimes of other countries.  The US is usually the country of
comparison in this area.  Brief details of the US regulatory regime are set out below to
provide an initial point of reference.
3.2 860DUNHWLQJ$XWKRULVDWLRQV
In the US, the principal regulatory agency is the FDA.  The criteria for authorisation applied by the
FDA are essentially the same as the European criteria but the trials which the applicant
carries out to generate data for the application must comply with FDA regulations which, in
certain circumstances, may vary from the equivalent European standards.  The FDA will
accept reports of foreign clinical trials but it is uncommon for the agency to approve a
product without some evidence from clinical trials conducted in the US.  Once granted, as
for Europe, marketing authorisations are generally granted for a five year period and
renewable for five year periods thereafter, subject to powers to vary, suspend or revoke any
marketing authorisation
3.3 0HGLFDO’HYLFHV
US regulators require that the manufacturers of most medical devices submit information to
the FDA, via the Centre for Devices and Radiological Health, and receive clearance before
a product is introduced onto the market.  Devices are classified into one of three classes,
depending on the degree of risk imparted to patients by the device.  The regulatory
requirements are more onerous in respect of high risk devices i.e. Class III devices, than
lower risk devices i.e. Classes I and II.
A new device may be introduced to the US either via a pre-market notification (a so-called
510(K)), or via a Pre-Market Approval Application ("30$").  Under the 510(K) procedure,
the applicant must submit certain information to the FDA (including the trade and common
name, labelling and advertising details, intended use and directions for use and the
classification of the device) to establish that the device is "substantially equivalent" to other
devices currently being offered for sale in the US.  If the FDA is satisfied with the
information submitted, then the manufacturer is authorised to market the device in the US,
so long as the production process complies with the requirements for Good Manufacturing
Practice.  It generally takes from three to twelve months from the date of a submission to
obtain clearance of a 510(K) application.
Devices with new technological characteristics, or with a different safety or efficacy profile,
will not be substantially equivalent and will require approval via the PMA procedure.  This
may involve, for example, a review of toxilogical, immunological and other data, in
addition to the examination of clinical results, where available.  FDA review of a PMA
application generally takes one or two years from the date the application is accepted for
filing, but can take significantly longer.
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$11(;
5HJXODWLRQRIWKH$GYHUWLVLQJ
DQG3URPRWLRQRI0HGLFLQDO3URGXFWV
1. *HQHUDO
At present regulation of the advertising and promotion of medicinal products operates at a national
level.  Many countries have a combination of self regulatory codes (generally created and
enforced by their national pharmaceutical association) and national legislation (generally
enforced by government bodies).
There have been attempts to create international standards (for instance by WHO and the IFPMA -
see section 2 below), but despite these attempts, recent studies suggest that two thirds of the
world’s countries still do not have laws to regulate pharmaceutical promotion or do not
enforce the ones they have32.
The aim of regulation in this area is to create an acceptable balance between the supplier’s right to
produce commercial product information, intended to increase the sales of a pharmaceutical,
and the rights of consumers and health care professionals to independent objective product
information.  Until recently regulation on a national basis has been reasonably successful.
The system is now, however, being challenged and undermined due to the nature of the
Internet and the ability of users to access sites located in any territory which may carry
material which does not comply with the regulations of the country in which the user is
located.  This can be problematic for the consumer, used to being able to rely on regulated
information, being exposed to unregulated material.  It can also be problematic for suppliers,
exposing themselves to the scrutiny of a whole network of regulatory bodies in territories in
which they are not consciously operating.
Section 2 provides an account of the various international codes of practice on this subject - Section 3
provides an account of regulation at the European level and within EU member states, using
the UK as a particular example.  Section 4 contrasts the system in the US.  Section 5
describes attempts to harmonise national systems and to create a consistent approach which
is capable of dealing with medium of the Internet.
2. ,QWHUQDWLRQDO5HJXODWLRQ
Over 10 years ago WHO published ethical criteria on all aspects of pharmaceutical advertising and
promotion.  The ethical criteria establish a set of broad and general standards for the
promotion of medicinal products.
WHO also recognises the International Federation of Pharmaceutical Manufacturers Association
(IFMPA) which is a non governmental organisation having as its members, either directly or
through regional organisations, the pharmaceutical industry associations of 50 countries in
all parts of the world33.  IFMPA represents the research-based pharmaceutical industry and
32
 "Blurring the Boundaries: New Trends in Drug Promotion", Barbara Mintzes, Health Action International, 1998.
33
 The countries where FAMA has Member Associations are:-
Argentina* Chile* Italy Poland
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other manufacturers of medicines which are intended for sale as prescription items or under
the supervision of health care professionals.
The IFPMA Code of Pharmaceutical Marketing Practices is consistent with WHO’s ethical criteria.  It
is a condition of the IFPMA Code that national associations should accept the conditions of
the Code on behalf of their member companies.  The Code sets minimum standards but some
countries choose to adopt a more demanding national code.
IFPMA enforces the code, dealing with all bona fide alleged breaches reported to it.  Where a breach
has been found to occur the objective is to effect a rapid correction of matters.  Publicity is
given to breaches of the Code and periodic reports are issued on the operation of the Code.
The Code sets out a series of general principles which cover standards of promotion, supporting
scientific evidence, provision of essential safety data, restrictions on the disguising of
promotions, pre-registration communications, communications to the public and internal
clearance of promotions.  The most general principle of the Code states that all promotional
material for pharmaceutical products should be:-
(a) accurate;
(b) fair;
(c) objective; and
(d) presented in such a way so as to:-
(i) conform with legal requirements and high ethical standards; and
(ii) be in good taste.
The International Code also has sections dealing with the training and conduct of Medical
Representatives, conduct of symposia, congresses and other means of verbal communication,
hospitality, printed promotional material, audio-visual and computer based promotional
material and samples.
                                                                                                                                                                    
Australia Colombia* Japan Portugal
Austria Denmark Kenya Singapore
Belgium Ecuador* Korea South Africa
Bolivia* Finland Malaysia Spain
Brazil France Mexico* Sri Lanka
Canada Germany Morocco Sweden
Central America*: Greece Netherlands Switzerland
&RVWD5LFD Hong KongNew Zealand Thailand
*XDWHPDOD India Norway Turkey
+RQGXUDV Indonesia Pakistan UK
1LFDUDJXD Ireland Peru* Uruguay*
(O6DOYDGRU Israel Philippines USA
Venezuela*
* Latin American associations are affiliated to IFPMA through their membership of the regional Federation
FIFARMA.
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Under the Code, communication directly to the consumer is only permitted if it is allowed under local
laws and then it must be accurate, fair and not misleading.  This clearly allows for
significant variations between countries on their approach to direct to consumer advertising.
3. 5HJXODWLRQZLWKLQWKH(8
At the community level, regulation in the EU is again both legislation based and self imposed.
3.1 6HOI5HJXODWLRQ
The European Federation of Pharmaceutical Industries Association (EFPIA) is the representative
body of the pharmaceutical industry in Europe.  Its members are the national industry
associations of the sixteen pharmaceutical - producing countries in Western Europe.
The EFPIA has adopted the European Code of Practice for the Promotion of Medicines which is
consistent with European legislation and which sets out the minimum standards which the
EFPIA considers must be adopted and enforced by its member associations.  Individual
members must adopt the European Code or ensure that their own national codes fully reflect
the standards of the European Code in a manner compatible with national laws.
Enforcement of the European Code (or relevant national code) is the responsibility of each
member association in their respective territory.
The European Code is compatible with the International Code but includes greater detail and more
rigorous and specific requirements in certain cases.  For example, it states that promotional
material must include "essential information compatible with the summary of product
characteristics and the classification for the supply of the product".  This is not addressed
specifically by the International Code, although it may be covered by some of the general
principles.
The EFPIA Code does not apply to direct-to-consumer advertising which is covered by the European
Code of Standards for the Advertising of Medicines.  This Code was adopted in 1977 by the
Proprietary Association of Europe.  It only relates to certain over the counter (OTC)
medicines as promotion of prescription medicines and some OTC medicines is not permitted
under EC Law (see section 3.7 below).
3.2 /HJLVODWLRQ
Relevant EU legislation can be divided into that which is specifically directed to the promotion of
medicinal products and that which is directed to advertising in general.
&RXQFLO’LUHFWLYH ((& on the advertising of medicinal products for human use contains a
series of restrictions and guidelines directed specifically to pharmaceuticals.  The material
provisions are as follows:-
(a) the advertising of medicinal products which are not authorised in the community is
strictly prohibited (Article 2);
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(b) direct-to-consumer advertising of medicinal products which are only available on
prescription (and certain other products for which self-medication is not suitable) is
prohibited (Article 3); and
(c) where it is permitted, the advertising to the general public of medicinal products
must be in conformity with the very strict provisions laid down in the Directive
(Article 4 and 5).
Certain aspects of the Directive are optional, and it is left to member states to decide, for example:-
(a) specific rules in relation to products the cost of which may be reimbursed (Article
3(3));
(b) whether to impose more onerous obligations in respect of information to be included
in promotions (Article 4(1)(b)); and
(c) the number of samples which can be provided to a health professional (Article
11(2)).
This has resulted in a degree of non-harmonisation in the EU.  In relation to point (c) above, for
example, the number of samples that can be provided to a health professional is limited to
one per product per year in Finland and Norway, ten in the UK and in Belgium a total of no
more than 600 samples per year for all products34.
&RXQFLO ’LUHFWLYH ((& DPHQGLQJ ’LUHFWLYH ((& on the co-ordination of certain
provisions laid down by law, regulation or administrative action in member states
concerning the pursuit of television broadcasting activities, applies to advertising in general
but it contains a total ban on advertisements and teleshopping in relation to all medicinal
products, including OTCs (Article 14).
&RXQFLO’LUHFWLYH((&relating to the approximation of laws, regulations and administrative
provisions of member states concerning misleading advertising contains regulations on
advertising of general applicability.  The Directive requires member states to implement
adequate and effective means for controlling misleading advertising in the interests of
consumers, competitors and the general public.
3.3 5HJXODWLRQZLWKLQPHPEHUVWDWHVWKH8.H[DPSOH
As stated above, the EU Legislation has not totally harmonised advertising practices within the EU.
Taking the UK as an example, there is still a complex network of regulations relating to the
advertisement of medicinal products.
On the legislative side, the Medicines Act 1965 contains specific provisions relating to promotions
and advertising.  Under Part VI of the Act (sections 92 - 97) licensed products must not be
recommended for any uses other than those listed in the licence and no false or misleading
advertisements or representations can be made in relation to licensed medicines.  The act is
enforced by the Department of Health.
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The 1992 EU Advertising Directive is implemented by the Medicines (Advertising to the Public)
Regulations 197835.  The regulations are enforced by the MCA.
The 1984 EU Misleading Advertising Directive is implemented by the Control of Misleading
Advertisements Regulations 198836.  These regulations are enforced by the Office of Fair
Trading.  The Director General of Fair Trading can apply to the High Court for an injunction
preventing the further publication of a misleading advertisement.  Most complaints are
handled by the Advertising Standards Authority (ASA) or local trading standards
department.
Recently in the UK, local trading standards departments have joined forces with their international
counterparts (led by the Australian trading standards authorities) to carry out a global sweep
of the Internet for health scams.  Operators of sites such as one US site which promotes
"herbal remedies which can make you cancer free" were warned that it is not necessarily the
law of the site in which they reside that applies to their activities37.  The results of the sweep,
which was aimed at maintaining an enforcement presence on the net, are being collated by
the Australian Competition and Consumer Commission and will be available in due course.
On the self regulatory side, the UK has general regulations in the form of the British Codes of
Advertising and Sales Promotion which cover all forms of advertising.  The Code is co-
ordinated by the Committee of Advertising Practice and enforced by the Advertising
Standards Authority which promotes the highest standards in non-broadcast advertisement in
the UK.
Industry specific self regulation comprises a series of codes including:-
(a) the Association of British Pharmaceutical Industry (ABPI) Code of Practice for the
Pharmaceutical Industry which controls the promotion of prescription
pharmaceuticals; and
(b) the Proprietary Association of Great Britain (PAGB) Codes of Practice which
control non-prescription pharmaceuticals (including the PAGB Professional and
Consumer Codes).
The ABPI Code of Practice is consistent with the 1994 Regulations but imposes stricter requirements
than the 1992 Directive.  The Code covers all sales promotion, in whatever form and
whatever the mechanism of communication (including promotions on the Internet).
Compliance with the Code is obligatory for ABPI member companies.
Complaints submitted under the Code, the majority of which are from healthcare professionals, are
considered by the Code of Practice Panel, the decision of which can be appealed to the Code
of Practice Appeal Board.  Where breach of the Code is ruled the company concerned must
                                                                                                                                                                    
34
 "The Internet and the Code of Practice for the Pharmaceutical Industry", Heather Simmonds of the ABPI.
35
 SI 1978/41.
36
 SI 1988/915.
37
 Office of Fair Trading press release No. 38/98.
- 52 -
give an undertaking that use of the material has ceased forthwith and that all possible steps
have been taken to avoid a similar breach of the Code in the future.
The ABPI has been pro-active in formulating a policy in respect of Internet complaints and
publishing guidelines on their approach to advertising on the Internet.  The ABPI’s view is
that whilst the Code applies to Internet promotions, it is only enforceable in respect of
information put on the Internet by companies operating in the UK.  The ABPI will only take
action in relation to advertisements placed on the Internet outside the UK if use of the UK
product is specifically referred to or the site is otherwise promoted in the UK e.g. by
medicinal representatives of the company promoting the site.
The ABPI received a complaint in May 1997 about an Internet site run by Janssen-Cilaq and
Organon, which was on a Belgian server and which referred to the site owners product,
Risperdal.  On appeal, no breach of the Code was ruled38.  The fact that the server was not in
the UK, that no information specific to the UK product had been added and that the
information had to be "pulled" by a searcher (i.e. by surfing the net) and was not "pushed"
by the company was instrumental in the decision reached.  The approach of the ABPI which
is illustrated by this case is that if the information provider is not really intending to
advertise in the UK then it will not fall foul of the UK regulations.
3.4 5HJXODWLRQZLWKLQ0HPEHU6WDWHVWKH*HUPDQH[DPSOH
Regulation of advertising and promotion of medical products is provided for by a specific law
(“Gesetz ueber die Werbung auf dem Gebiet des Heilwesens-HWG”) and additionally by a
general law covering any unfair practices in competition independent of the nature of the
practice and of the product (“Gesetz gegen den unlauteren Wettbewerb-UWG”). The HWG
constitutes public law whereas the UWG constitutes private law.  There is also a degree of
self regulation.  Dealing with each in turn:-
(a) In the past, the HWG had been amended several times for the purposes of
implementing (the above mentioned) Council Directives dealing with advertising and
promotion of medical products. Save for some exceptions, the law does not only
apply to direct-to-consumer advertising but covers any advertising of medical
products independent of the addressee.
According to the HWG, any false or misleading advertisement of medical products
falling within the scope of application of the “Law relating to the Manufacture and
Distribution of Pharmaceuticals” (“Arzneimittelgesetz-AMG”) is prohibited.
Advertising of medical products which are subject to prescription or which are
neither authorised in Germany nor in another Member State of the European Union is
entirely prohibited. Advertisements must provide for specific information as to the
pharmaceutical’s effects, side-effects, contraindications etc (paragraph 1 of Section 4
HWG). The information must be visibly separated from other advertising
information. According to Section 4a HWG, leaflets inserted in the packages of
medical products shall not include advertisements for other medical products.
38
 Case Auth/543/5/97 and Auth 544/5/97.
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The HWG is enforced by the health care authority of that federal state (“Bundesland”) in
which the individual or establishment violating the provisions of the HWG is
domiciled.
(b) The UWG constitutes the general law protecting competitors against any unfair or
misleading advertisements. Any infringement of the provisions of the HWG
simultaneously constitute a violation of Section 1 of the UWG and may therefore be
challenged by competitors of the person or establishment responsible for the
advertisement. However,  the UWG may also cover advertising and promotion
practices which do not fall within the scope of application of the HWG. In a case of
1987 the German Supreme Court ruled that the consumer is mislead by an
advertisement in which the manufacturer of a medicine is named with the German
academic title “professor” without any clarifying addition as to the fact that the title
was not conferred on him by a German university but in South America. The HWG
was not applicable to this advertising measure. However, the court held that the use
of the foreign academic title constituted a misleading advertisement prohibited by
Section 1 of the UWG.
Furthermore, it is worth mentioning that on the grounds of the UWG, the German courts
strictly prohibit comparative advertising.
The UWG is not enforced by any specific body but by private action. The law only applies if a
competitor sues another competitor for unfair advertising practices in competition.
(c) Industry-specific self-regulation is imposed on members of the Association of the
German Pharmaceutical Industry by a special code (“Kodex der Mitglieder des
Bundesverbandes der pharmazeutischen Industrie”). Apart from prohibiting false and
misleading advertisements, the code contains specific rules according to which a
manufacturer of medical products is obliged to study any extraordinary incidents
with regard to a specific medical product he produces to the Regulatory Authority.
Furthermore, the code contains rules for the scientific co-operation of doctors and
the pharmaceutical industry.
As the code constitutes self-imposed regulations it is enforced by the association.
Section 10 AMG sets out the requirements for labelling of medical products. The Section complies
with the Leafleting and Labelling Council Directive 92/97/EEC of 31 March 1992. The label
of a medical product offered for sale in Germany has must be written in the German
language.
3.5 5HJXODWLRQZLWKLQ0HPEHU6WDWHVWKH,WDOLDQH[DPSOH
In relation to Italy, particular provisions apply to a category of professionals ("information
scientific") the role of which is to promote the marketing of medicinal products as well as
equipment essentially with hospitals and medical practices. These professionals must satisfy
specific requirements and are registered on an DGKRF register. They cannot be equalised to
distributors, because they do not have the power to sell products on behalf of their principal.
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Also, they are not agents, because they do not (directly) promote sales but are specifically
entrusted with the activity of illustrating the features of a given product or device.
It is worth noting that their activities although subject to administrative scrutiny are carried out on
behalf of companies and not for the direct benefit of consumers.  It is difficult to transport
their current role to that of an E-commerce environment.  Their position, however, is one on
which views will need to be sought in relation to E-commerce advertising in Italy.
3.6 5HJXODWLRQZLWKLQ0HPEHU6WDWHVWKH%HOJLDQH[DPSOH
(a)  5HJXODWRU\IUDPHZRUN
The regulation of advertising and promotion of medicines is primarily set out in the
Medicines Law of 25 March 1964 (:HWRSGH*HQHHVPLGGHOHQ/RLVXUOHV0pGLFDPHQWV
the ‡/DZ·) as recently amended by the Law of 20 October 1998 published in the Belgian
Official Gazette on 11 November 199839 and the Royal Decree of 7 April 1995 on the
information and advertising of medicines intended for human consumption (.RQLQNOLMN
%HVOXLW EHWUHIIHQGH GH YRRUOLFKWLQJ HQ UHFODPH LQ]DNH JHQHHVPLGGHOHQ YRRU PHQVHOLMN
JHEUXLN$UUrWp5R\DOUHODWLYHjO¶LQIRUPDWLRQHWjODSXEOLFLWpFRQFHUQDQWOHVPpGLFDPHQWV
jXVDJHKXPDLQ the ‡’HFUHH·). The Decree brings into effect the 1992 EU Advertising
Directive.
Furthermore, unlawful or misleading advertising practices for medicines can also be
sanctioned under the general Fair Trade Practices Act of 14 July 1991 (:HWEHWUHIIHQGHGH
+DQGHOVSUDNWLMNHQ HQ GH 9RRUOLFKWLQJ HQ %HVFKHUPLQJ YDQ GH &RQVXPHQW  /RL VXU OHV
3UDWLTXHV GX &RPPHUFH HW VXU O¶,QIRUPDWLRQ HW OD 3URWHFWLRQ GX &RQVRPPDWHXU For
present purposes we will only focus on the rules specifically relating to medicines.
E  5HVWULFWLYHXVHRIDGYHUWLVLQJDQGGLVVHPLQDWLRQRILQIRUPDWLRQRQPHGLFLQHV
The Decree contains the rules on advertising of and the dissemination of information about
medicines. It provides, LQWHU DOLD rules about the information which should be stated on
instructions, advertising to the public and to medicinal professionals and general
information on the medicine.
With regard to advertising, the general rule of the Law is that advertising of medicines is
prohibited for unlicensed medicines and advertising intended for the public is in any case
prohibited for prescription medicines and medicines remedying certain diseases as
identified by the High Health Council (+RJH *H]RQGKHLGVUDDG  &RQVHLO VXSpULHXU
G¶K\JLqQHSXEOLF). Further details relating to advertising are set out in the Decree.
The Decree states, LQWHUDOLD, that advertising of licensed medicines should emphasise the
rational use of the medicine and may not be misleading. Furthermore the advertisement of
licensed medicines is prohibited through certain defined means including software
programmes and billboards.
39
 The amendments set out in the Law of 20 October 1998 do not affect the discussed rules on the advertisement
and promotion of medicines.
- 55 -
(c)  $GYHUWLVLQJRQUDGLRDQGWHOHYLVLRQ
With regard to advertisements of licensed medicines intended for the public, the licence
holder has to obtain an authorisation for the advertisement on radio and television. Note that
the Internet is not been covered by this rule. The Belgian regulators are of the view that it is
impossible to supervise information flow relating to medicines on the Internet.
The competent authority is the Minister of Public health (0LQLVWHU YDQ 6RFLDOH =DNHQ
9RONVJH]RQGKHLGHQ/HHIPLOLHX0LQLVWUHGHV$IIDLUHVVRFLDOHVGHOD6DQWpSXEOLTXHHWGH
O¶(QYLURQQHPHQW  The Minister acts upon the advice of the Supervising Commission for
the Advertisement of Medicines (GH &RPPLVVLH YDQ 7RH]LFKW RS GH UHFODPH YRRU
JHQHHVPLGGHOHQ  /D &RPPLVVLRQ GH &RQWU{OH GH OD SXEOLFLWp GHV PpGLFDPHQWV The
request for authorisation has to be lodged by the licence holder of the medicine with the
General Pharmaceutical Inspector ($OJHPHQH )DUPDFHXWLVFKH ,QVSHFWLH  ,QVSHFWLRQ
*pQpUDOHGHOD3KDUPDFLH who is in charge of administering the application.
Once the authorisation is granted, the advertisement can be repeatedly used by the
advertiser during an initial term of two years and an extension of this time limit can be
granted upon request.
3.7 5HJXODWLRQZLWKLQ0HPEHU6WDWHVWKH)UHQFKH[DPSOH
Only medicines which have an authorisation for market release (AMM, the French
equivalent of a marketing authorisation)) may be advertised.  An AMM is granted by the
Director General of the Medicines Agency (Agence due Médicament).
There is a distinction between advertising to the general public and advertising to the
medical profession as follows:-
(i) Advertising intended for the public
For medicines, the conditions are:
• medicines must not be subject to medical prescription
• medicines must be non-refundable
• the AMM of the medicine in question must not carry any restriction in respect of
advertising
In addition, advertising permit is required, the conditions for which are :-
• Prior authorisation granted by the Director General of the Medicines Agency for
most products.
• Products labelled "beneficial for health" are dealt with by the Ministry of Health.
• The advertising permit is granted following a consultative procedure carried out
by the Advertising Control Commission (FRPPLVVLRQGHFRQWU{OGHODSXEOLFLWp
(ii) Advertising intended for the medical profession:
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Special rules apply to advertising in this area, with a degree of professional self-regulation.
Memorandum and recommendations from an ethics committee are the means of establishing
the principles of self-regulation in areas where regulation is unclear or silent.
4. 5HJXODWLRQLQWKH86
The Federal Food, Drug and Cosmetic Act contains the main US provisions relating to advertising
and promotion of pharmaceuticals in the US.  The regulations are implemented and enforced
by the FDA.
The most significant difference between the US and EU position is that direct-to-consumer
advertising of prescription products is not prohibited in the US, although the content of such
advertisements is the subject of tight control.  The Division of Drug Marketing, Advertising
and Communications is the organisation in the FDA responsible for regulating prescription
pharmaceutical promotion.
The FDA has not yet issued any guidance on its approach to advertising on the Internet, expressing
the view that the Internet as just another promotional medium and the existing regulations
and guidelines cover the practice.  This view was reached following extensive public
consultation on the issues arising from Internet trading.  Debate in the US over use of the
Internet has focused on, amongst other things, whether promotions on the Internet qualify as
labelling or advertising and consequently which specific regulations should apply.  The main
difference between the regulations is the requirement for full disclosure in relation to labels
compared to a brief product summary for advertisements.  Most companies which post
product information have opted to comply with the stricter labelling regulations and have
included the package insert for products featured on their web-site.
As a result of the differences between the EU and US regimes, consumers can now view
advertisements in relation to prescription pharmaceuticals (and in certain cases purchase
such pharmaceuticals) on US web sites.  So long as the sites do not specifically refer to UK
products the approach of the UK authorities at least is that such sites do not fall within their
jurisdiction.
5. 6WHSVWRKDUPRQLVDWLRQ
One approach to harmonisation is that adopted by the UK authorities - only police those sites which
are directed at, and intended to, reach the UK public (even if the UK public has easy access
to them).  Such an approach may be sufficient in relation to sites regulated by the FDA but
the same may not apply to sites in territories with no regulation or control of the quality and
content of pharmaceutical advertising.
The World Health Organisation (“:+2”) is adopting a different approach.  Following a number of
Working Group Meetings in 1997 and 1998, the World Health Assembly adopted a
resolution in May 1998 on cross border advertising, promotion and sale of medicinal
products through the Internet.
The WHO resolution calls for member states to review existing regulations and guidelines and to
collaborate to ensure that adequate cover is implemented, monitored and enforced.  The
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resolution also encourages the industry to formulate an acceptable international self-
regulatory systems and to maintain legal and ethical standards in cross-border advertising.
6. 2WKHULVVXHV
Many commentators have focused on the unique nature of Internet communications as a means of
overcoming the cross-border regulatory issues.  They note that on the Internet, it is the
customer/patients who initiates contact with a web-site and not the owner of the site.  People
are seeking out information "with every click of their mouse".  Queries have accordingly
been raised as to whether advertising on the Internet is in fact direct-to-customer advertising
or indirect communication.  Indirect communication about prescription medicines is
permitted under most regulatory regimes so long as it is of a "non-promotional" nature.
Although this can lead to disputes as to what constitutes information and what strays into
promotion - the interpretation of Internet communication as "indirect" could be adopted as
an approach in certain circumstances to overcome the cross-border issues.
Following on from the above point, it is possible that the best approach to dealing with the flood of
apparently unregulated information on the Internet is through positive steps, such as
consumer education.  In line with this, the WHO is co-ordinating the generation of a “Guide
for Internet Users” specifically aimed at pharmaceutical products.  Such measures could be
combined, for instance, with approval by national regulatory authorities (via there own web
sites perhaps) of specifically authorised web sites.  Accredited web sites could then carry a
“smart” accreditation symbol (like the CE mark) which linked directly to that list (so that
mere copying of the symbol by pirate sites would be insufficient for them to claim to
consumers that they were accredited).
As mentioned above, in the US labelling regulations, which are more onerous than advertising
regulations, are thought by some to apply to all Internet promotions.  On this interpretation
the Labelling Directive (92/27/EEC) would apply to EU Internet advertisements.  This
Directive requires that medicinal products must be labelled in the language of the country
where the product is placed on the market, and must contain a patient package leaflet in that
language.  Whilst the nature of the Internet is such that it is not necessarily problematic or
financially prohibitive to add more information to a site this is a further requirement with
which companies using the Internet must contend.
There are peripheral laws and regulations relating to advertising which may also cause cross border
problems.  For example, the rules relating to comparative advertising are very different in
the US and Europe.  In the US, comparisons which would be considered acceptable may
amount to trade mark infringement in the EU.  Site owners would need to take into account
the differences in such rules.
The above account only sets out the regulations affecting suppliers seeking to advertise medicinal
products on the Internet.  If they seek to go one step further and sell via the Internet, other
regulations will affect their activities.  For example, under Article 14 of the Distance Selling
Directive (97/7/EEC), member states are entitled to prohibit any distance selling of
medicinal products in their territory, which would theoretically cover Internet transactions.
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$11(;
-XULVGLFWLRQRYHU,3GLVSXWHV
1. ,QWURGXFWLRQ
Jurisdiction is by far the most problematic and vexed legal issue relating to the Internet
generally, and E-commerce in particular.  It is far from clear to what extent the mere fact of
having a web-site will subject the site owner to the laws of the given country.  There are
currently no specific laws which deal with E-commerce which means that the starting point
is from the normal rule that the owner of an intellectual property right can take action to
enforce that right in the courts of the country where an infringement takes place.  At present
each case must be considered on its own facts and, in many instances, the answer will
depend upon the laws enforced in the country in which the question is being raised.
However, due to a lack of legislation dealing specifically with cross-border Internet related
transactions, national courts are having to adapt traditional concepts of jurisdiction.
Jurisdictional issues in relation to E-commerce are not industry specific; the pharmaceutical
sector will face the same problems as other industry sectors in this regard.  However, the
pharmaceutical industry is strongly reliant on intellectual property rights, in particular,
patents, trade marks, copyright, and confidential information/know-how (",35") and their
protection.  The purpose of this Annex is to provide a general introduction to jurisdictional
issues in this area, concentrating on where infringement of IPRs occur and which country
has jurisdiction over that infringement.  UK law is used as the basis for discussion in each
case.  However, given the relative harmonisation of IPR laws throughout the Community, the
issues raised are likely to apply through-out Europe.
2. :KHUHGRHVLQIULQJHPHQWRFFXU"
2.1 There do not appear to be any clear rules giving a clear indication of where infringement of
IPR occurs over the Internet.  The most common discussion concerns whether infringement
occurs in the country of location of the server or whether it occurs in the country in which
the material is downloaded.  A discussion of the position in relation to IPR of most relevance
to the pharmaceutical industry is set out below.
(a) &RS\ULJKWLQIULQJHPHQW
Copyright is the exclusive right to reproduce certain types of creative works.  It arises
automatically upon the creation of such works without the need for registration.  In
the UK, the law is governed by the Copyright, Designs and Patents Act 1988 (the
"1988 Act").  Section 1 of the 1988 Act states that copyright subsists in the following
categories of work:
D RULJLQDOOLWHUDU\GUDPDWLFPXVLFDORUDUWLVWLFZRUNV
E VRXQGUHFRUGLQJVILOPVEURDGFDVWVRUFDEOHSURJUDPPHVDQG
F WKHW\SRJUDSKLFDODUUDQJHPHQWRISXEOLVKHGHGLWLRQV
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It is worth noting that a ’literary work’ is defined to mean any work which is written, spoken or
sung and includes tables or compilations and, importantly, computer programs.  The
application of copyright law to computers was clarified by the amendment of the
1988 Act by the Copyrights (Computer Programs) Regulations 1992.  These
regulations were brought in to harmonise UK law and that of other EC Member
States in accordance with the Directive for the legal protection of Computer
Programs40.  Copyright will also protect the preparatory design material for a
computer program.  "Literary work" has also been defined to include databases by
The Copyright and Rights in Databases Regulations 199741 which implement a
Directive harmonising the copyright laws of EC Member States on the legal
protection of databases.
The following provisions of the 1988 Act are also relevant:-
(i) the general rule is that the owner of a copyright work is the person who
creates it (section 9) (there are exceptions in relation to employees and certain
categories of copyright such as crown copyright);
(ii) copyright does not subsist in a literary, dramatic or musical work unless and
until it is recorded "in writing or otherwise" (section 3(2));
(iii) the literary, dramatic, musical or artistic work must be ’original’ (section 1).
In the UK, there is a low threshold of originality and the basic requirements
are that the work originated from the author and is the result of minimum
skill, effort or judgement;
(iv) the owner of the copyright in a work has the exclusive right to copy the work,
issue copies of the work to the public, perform, show or play the work in
public, broadcast the work or include it in a cable programme service or make
an adaptation of the work, in the UK (section 16).  Copyright is thus infringed
by the carrying out of any of these acts;
(v) the 1988 Act also sets out, at chapter IV, certain moral rights of authors,
which are the rights to be identified as author of the work, the right to object
to derogatory treatment of the work and the right to object to false attribution
of the work;
(vi) an infringement of copyright is actionable by the copyright owner.  The
remedies available for infringement of copyright include damages or an
account of  profits, injunctions, order for delivery up or destruction of
infringing copies, and costs (Chapter VI).
In addition to the above provisions of the 1988 Act, as a result of the provisions of
the Directive harmonising the term of protection of copyright and certain related
40
 Directive 91/250, OJ 1991, L122.
41
 SI No. 1997/3032.
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rights42 the term of copyright protection for artistic, literary, dramatic and musical
works throughout the EC now generally expires 70 years after the death of the author
(Section 12, 1988 Act as amended by The Duration of Copyright and Rights in
Performances Regulations 199543.  For computer-generated works, sound recordings,
broadcasts, computer programs, the period of copyright protection is generally 70
years from the end of the calendar year in which such works were made available to
the public (Sections 12-14 1988 Act as amended).
The transmission of material over the Internet could infringe the copyright of a third
party.  Problems arise in determining who to sue (e.g. the access provider, the host or
the third party, each of whom could "copy" a copyright work) and where jurisdiction
lies.  There are no clear answers to these questions.  However, the two cases
discussed below give an idea of how courts are approaching the issue in Europe and
the US.
EC Council Directive 93/83/EEC relates to copyright applicable to satellite broadcasting and
cable retransmission but may be applicable to IPR by analogy. This Directive states
that the act of communication to the public by satellite occurs solely in the Member
State where the programme-carrying signals are introduced into an uninterrupted
chain of communication leading to the satellite and down towards the earth.  Further,
where the act of communication to the public by satellite occurs in a non-Member
State, if the programme-carrying signals are transmitted to the satellite from an uplink
station in a Member State, then that communication is deemed to have occurred in
that Member State.  If there is no use of such an uplink station but a broadcasting
organisation established in a Member State has commissioned a communication to
the public, then the communication is deemed to have occurred in the Member State
in which the broadcasting organisation has its principal establishment in the
Community.
The recent case of %ULWLVK6N\%URDGFDVWLQJ/WGY7KH3HUIRUPLQJ5LJKW6RFLHW\/WG44
considered this Directive and made the point that questions have arisen as to the
place where the broadcast takes place and what constitutes the act of broadcasting.
Section 6(4) of the 1988 Act states that in the case of a satellite transmission the
broadcast occurs from where the signals were transmitted to the satellite. The
observation was made that the restricted act in which the copyright owner had the
exclusive right was the placing of broadcasting signals into this uninterrupted chain
of communication.  It could no longer be argued that the broadcasting took place
where the signals were received.  Therefore, a licence under the broadcasting right
carried with it the right to send signals via satellite to all EC member states.
The current uncertainty relating to copyright on the Internet can be illustrated by the US case of
3OD\ER\Y&KXFNOHEHUU\.  In this case, the defendants operated a Web-site in Italy which
contained a computerised version of Playboy Magazine in infringement of the plaintiff’s
copyright.  The plaintiff claimed that this violated an injunction granted in 1981 by a US
42
 Directive 93/98, OJ 1993 L290/9.
43
 SI No. 1995/3297.
44
 [1998] RPC 467.
45
 939 F.Supp.1032 (S.D.N.Y. 1996.)
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court against the publication of infringing copies of their publication.  The defendants
argued that this was the same as selling the magazine in Italy, where it was legal.  The court
held that, although the prohibited activity originated in Italy, it was received in the US
without difficulty and so infringed that injunction.
Copyright is one of the most challenging areas in European intellectual property law.  It is used to
protect many different kinds of work in fields where the speed of technological progress is
rapid and it is an area where there has been some disharmony between the laws of Member
States.  The European Commission has already implemented several initiatives to amend
copyright law to keep up with technological progress, including Directives on the Protection
of Computer Software, Databases, Term of Copyright, Satellite Broadcasting and Cable
Retransmission and Rental and Lending Rights.  A similar initiative may be useful in respect
of copyright and E-commerce issues such as jurisdiction.
(b) 3DWHQW,QIULQJHPHQW
Patent law throughout the Community is relatively harmonised because of the
European Patent Convention (signed in 1973) pursuant to which 17 European
countries including all the Member States of the European Community, have agreed
to a single examination and grant system through the European Patent Office.  Upon
grant, the patent becomes a separate right within each of the signatory countries.  In
addition, there is the Community Patent Convention 1975 ("&3&"), which is a treaty
between EC Member States providing for a Community wide patent.  The CPC is not,
however, yet in force.  The UK Patents Act 1977 (the "$FW") was intended to
amend UK national patent law to make provision for both the EPC and the CPC.  The
1977 Act provides the owner of an invention which is new, involves an inventive
step, is capable of industrial application and which does not fall within a specified list
of exceptions, a monopoly in respect of that invention for a period of 20 years from
the date of filing the application for the patent (sections 1 and 25).
Under section 60 of the 1977 Act, a person infringes a patent for an invention if,
while the patent is in force, any of the following things are done in the UK in relation
to the invention without the consent of the proprietor, namely:-
D ZKHUHWKHLQYHQWLRQLVDSURGXFWKHPDNHVGLVSRVHVRIRIIHUVWRGLVSRVH
RI XVHV RU LPSRUWV WKH SURGXFW RU NHHSV LW ZKHWKHU IRU GLVSRVDO RU
RWKHUZLVH
E ZKHUHWKHLQYHQWLRQLVDSURFHVVKHXVHVWKHSURFHVVRUKHRIIHUVLW IRU
XVHLQWKH8.ZKHQKHNQRZVRULWLVREYLRXVWRDUHDVRQDEOHSHUVRQLQ
WKH FLUFXPVWDQFHV WKDW LWV XVH WKHUH ZLWKRXW WKH FRQVHQW RI WKH
SURSULHWRUZRXOGEHDQLQIULQJHPHQWRIWKHSDWHQW
F ZKHUH WKH LQYHQWLRQ LV D SURFHVV KH GLVSRVHV RI RIIHUV WR GLVSRVH RI
XVHVRULPSRUWVDQ\SURGXFWREWDLQHGGLUHFWO\E\PHDQVRIWKDWSURFHVV
RUNHHSVDQ\VXFKSURGXFWZKHWKHUIRUGLVSRVDORURWKHUZLVH
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In relation to the E-commerce and the pharmaceutical industry, it is likely that most issues of
patent infringement, and whether or not there is jurisdiction to sue, are likely to arise in
relation to offering to dispose of products, offering a process for use and offering to dispose
of a product obtained directly be means of a process, over the Internet.  The problems are the
familiar ones, namely whether or not, as in the 3OD\ER\Y&KXFNOHEHUU\ case (discussed
in relation to copyright above), receiving, for example, an offer of sale of a product which is
legal in the country of origin, but which happens to be accessed in a country where such
offer infringes a patent right, constitutes patent infringement.  Uniformity of decisions on
these issues throughout Europe may be difficult because, despite harmonisation, there have
been examples of conflicting decisions as to what constitutes infringement in national courts.
The distortions created by the conflicting decisions of national courts within the EC will, in
theory, be resolved when the Community Patent Convention eventually comes in to force.
However, the position in relation to E-commerce infringement would benefit from guidelines
as to what will constitute patent infringement on the Internet.  There are no clear solutions.
One suggestion to deal with E-commerce issues relating to patents may be to attempt to
revise the Community Patent Convention to deal with E-commerce issues before it is
implemented.  Certainly, the existence of a unitary court structure and procedure at
Community level for resolving litigation, (as suggested by UNICE (the Union of Industrial
and Employer’ Confederations of Europe) in October of this year would provide a good basis
for dealing with patent litigation resulting from E-commerce.
F 7UDGH0DUN,QIULQJHPHQW
A trade mark is a sign (such as a name or logo) used by a business to distinguish its goods or
services form the same or similar goods or services coming from another source.  Trade
marks can be registered or unregistered and both types of trade mark can be licensed.
Domain names are also of relevance, particularly in relation to E-commerce and the
pharmaceutical industry.
Dealing with each in turn:-
(i) 5HJLVWHUHG7UDGH0DUNV
Trade mark rights are effectively national.  An application can be made to
register a trade mark in respect of specific goods or services at the relevant
country’s trade mark registry or through the Community trade mark, Madrid
Protocol and Madrid arrangement systems.  When the registration process is
complete the registered proprietor has a monopoly to use the mark in respect of
the specified or confusingly similar goods or services.  Registered trade marks
can last forever provided renewal fees are paid and the marks are not removed
from the register.  In the UK, the Trade Marks Act 1994 (the " $FW")
implements Council Directive No 89/104/EEC of 21 December 1988 to
approximate the laws of Member States relating to trade marks.  Section 10 of
the 1994 Act sets out the acts which infringe a UK registered trade mark as
follows:-
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$SHUVRQLQIULQJHVDUHJLVWHUHGWUDGHPDUNLIKHXVHV LQ WKHFRXUVHRI
WUDGHDVLJQZKLFKLVLGHQWLFDOZLWKWKHWUDGHPDUNLQUHODWLRQWRJRRGV
RUVHUYLFHVZKLFKDUHLGHQWLFDOZLWKWKRVHIRUZKLFKLWLVUHJLVWHUHG
$SHUVRQLQIULQJHVDUHJLVWHUHGWUDGHPDUNLIKHXVHVLQWKHFRXUVHRIWUDGHDVLJQ
ZKHUHEHFDXVH
− the sign is identical with the trade mark and is used in relation
to goods or services similar to those for which the trade mark is
registered, or
− the sign is similar to the trade mark and is used in relation to
goods or services identical with or similar to those for which
the trade mark is registered,
WKHUH H[LVWV D OLNHOLKRRG RI FRQIXVLRQ RQ WKH SDUW RI WKH SXEOLF ZKLFK
LQFOXGHVWKHOLNHOLKRRGRIDVVRFLDWLRQZLWKWKHWUDGHPDUN
$SHUVRQ LQIULQJHV D UHJLVWHUHG WUDGHPDUN LI KH XVHV LQ WKH FRXUVH RI
WUDGHDVLJQZKLFK
− is identical with or similar to the trade mark, and
− is used in relation to goods or services which are not similar to
those for which the trade mark is registered,
ZKHUHWKHWUDGHPDUNKDVDUHSXWDWLRQLQWKH8.DQGWKHXVHRIWKHVLJQ
EHLQJZLWKRXWGXHFDXVHWDNHVXQIDLUDGYDQWDJHRIRULVGHWULPHQWDOWR
WKHGLVWLQFWLYHFKDUDFWHURUWKHUHSXWHRIWKHWUDGHPDUN
)RUWKHSXUSRVHVRIWKLVVHFWLRQDSHUVRQXVHVDVLJQLQSDUWLFXODUKH
− affixes it to goods or the packaging thereof;
− offers or exposes goods for sale, puts them on the market or
stocks them for those purposes under the sign, or offers or
supplies services under the sign;
− imports or exports goods under the sign; or
− uses the sign on business papers or in advertising.
$SHUVRQZKRDSSOLHVDUHJLVWHUHGWUDGHPDUNWRPDWHULDOLQWHQGHGWREH
XVHG IRU ODEHOOLQJ RU SDFNDJLQJ JRRGV DV D EXVLQHVV SDSHU RU IRU
DGYHUWLVLQJJRRGVRUVHUYLFHVVKDOOEHWUHDWHGDVDSDUW\ WRDQ\XVHRI
WKH PDWHULDO ZKLFK LQIULQJHV WKH UHJLVWHUHG WUDGH PDUN LI ZKHQ KH
DSSOLHGWKHPDUNKHNQHZRUKDGUHDVRQWREHOLHYHWKDWWKHDSSOLFDWLRQ
RIWKHPDUNZDVQRWGXO\DXWKRULVHGE\WKHSURSULHWRURUDOLFHQVHH
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1RWKLQJLQWKHSUHFHGLQJSURYLVLRQVRIWKLVVHFWLRQVKDOOEHFRQVWUXHGDV
SUHYHQWLQJ WKH XVH RI D UHJLVWHUHG WUDGH PDUN E\ DQ\ SHUVRQ IRU WKH
SXUSRVHRILGHQWLI\LQJJRRGVRUVHUYLFHVDVWKRVHRIWKHSURSULHWRURUD
OLFHQVHH
%XWDQ\VXFKXVHRWKHUZLVHWKDQLQDFFRUGDQFHZLWKKRQHVWSUDFWLFHVLQ
LQGXVWULDO RU FRPPHUFLDO PDWWHUV VKDOO EH WUHDWHG DV LQIULQJLQJ WKH
UHJLVWHUHGWUDGHPDUNLIWKHXVHZLWKRXWGXHFDVHWDNHVXQIDLUDGYDQWDJH
RURULVGHWULPHQWDOWRWKHGLVWLQFWLYHFKDUDFWHURUUHSXWHRI WKH WUDGH
PDUN
Registered trade marks are enforced by taking infringement proceedings in
the High Court against an infringer in relation to the above;
(ii) 8QUHJLVWHUHG7UDGH0DUNV
Unregistered trade marks are simply marks used by a party to identify goods
or services, or any trading or business names used by a party, which have not
been registered.  In appropriate circumstances, the owner of an unregistered
trade mark or trading/business name may be able to prevent third parties from
using the same or a similar mark or name.  In the UK, an action of this sort
would be based on the common law of ’passing-off’ (in which a trader who
has established a significant reputation and goodwill in his marks can restrain
a third party from using similar marks if he can prove that use of those
similar marks by the third party has caused the public to confuse the third
party’s goods with his own).  In most other European countries there will be a
similar right to restrain others from using the mark through an action for
unfair competition;
(iii) ’RPDLQ1DPHV
A domain name is an alphanumeric representation of an electronic machine
readable address (called an Internet Protocol Address) which is used by
networking computers (including those which operate the Internet) to route
messages from the sender to the recipient.  Registration for domain names is
carried out by non-profit making companies appointed for this purpose by the
Internet Society, an international body created for the purpose of co-
ordinating the Internet, on a first-come first-served basis.
A domain name forms an important part of an e-mail address (e.g.
Adam.Smith@Company.com) or of a business (or other person’s) home page
website address.  It consists of two elements, a word/number designated by
the proposed registrant and a generic designation known as a top level
domain such as ".com" or ".co.uk" for commercial entities.  Although the
suffix ".com" is specific to the regulatory company for the US ("Network
Solutions Inc") it has become established as a suffix for commercial entities
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operating on an international basis.  The UK equivalent (".co.uk") is
regulated by Nominet UK Limited.  It is typical for a company to want to use
its name or the words which feature in its most important trade marks as part
of such a website or e-mail address.  In order to obtain a domain name the
applicant must apply to one of the not-for-profit companies which were set up
to register domain names which are allocated on a first-come, first-served
basis.
The process of allocating names has created some difficulties for trade mark
owners.  A number of companies with well-known brand names were rather
slow in identifying the increased usage of domain names or decided not to
register all possible domain names simply by dint of the sheer number and
possible variety.  As a result, a number of applications were made for domain
names featuring well known trade marks by individuals who were not the
proprietors of such trade marks.  In some cases, offers were made to sell the
domain names to the proprietors of the trade marks sometimes for not
inconsiderable sums.  This has led to a number of disputes both in the UK
and elsewhere, which the regulatory companies and their dispute resolution
procedures have (in broad terms) been unable to resolve.  A number of these
matters have therefore been the subject of court proceedings.  In %ULWLVK
7HOHFRPPXQLFDWLRQVSOFDQGRWKHUVY2QH LQD0LOOLRQ the High Court
held that a trade mark owner could obtain a final injunction to restrain the
threatened use of its trade mark as part of a domain name and to require to
take steps to "transfer" the domain name registration to it.
The registrants of domain names have also attempted in some cases to
register the domain names as trade marks.  The UK Trade Marks Registry has
issued a statement indicating that domain names can be trade marks and may
be registered according to the normal rules but that the usual domain name
endings such as “.com” are to be regarded as not having any distinctive
character.  In these circumstances there would appear little to be gained in
attempting to register a domain name consisting purely of an already
registered trade mark and a domain name ending.
(d) &RQILGHQWLDO,QIRUPDWLRQ
Confidential information encompasses technical information and know-how and other
expertise which is not generally known or available.  In the pharmaceutical business, it is not
uncommon for a company to disclose confidential information to third parties or for third
parties to disclose confidential information to it (e.g. for the purposes of evaluating joint
product development opportunities).  This area of IPR is not subject to legislation in the UK.
Certain pre-conditions to establish breach of confidentiality have been set out by case law,
namely that the information must not be generally available, it must be imparted in
circumstances importing an obligation of confidence and there must have been an
unauthorised use of that information to the detriment of the party communicating it.  The
main problem as regards the transmission of confidential information over the Internet is
lack of security, coupled with a difficulty in establishing an express contractual obligation of
- 66 -
secrecy with parties such as an Internet service provider or any third party who accesses the
information by chance and passes it on.  Protection options for pharmaceutical companies at
the moment include the use of encryption, clear notices informing recipients of the
information that there is an obligation of security in respect of it and the use of intranets to
exchange confidential information between authorised users only.  In addition, it may be
appropriate to create specific legislation to deal with breach of confidential information in
relation to E-commerce.
3. (QIRUFHPHQW
3.1 *HQHUDO
Currently, the enforcement of IPRs is carried out by national courts on a case by case basis, which
enforce the right to take action in the courts of a country where infringement of an IPR right
takes place.  This right is also set out in the Brussels Convention 1968.  The Convention
rights and Court rights are discussed below.  In relation to E-commerce, the question for
discussion is whether these conventions need to be amended to cover E-commerce
jurisdiction in general, which would  have general applicability to all industries, including
the pharmaceutical industry.
3.2 &RQYHQWLRQ-XULVGLFWLRQ
(a) The Brussels and Lugano Conventions
Where the parties involved in the international contract are European, the relevant
principles will normally be found either in The Brussels Convention on Jurisdiction
and the Enforcement of Judgments in Civil and Commercial Matters 1968 (the
"Brussels Convention") (entered into by the Member States of the European Union)
or The Lugano Convention.  The principles which apply according to the choice or
otherwise by the contracting parties of a governing jurisdiction are set out below.
(i) 7KHSDUWLHVFKRRVHDMXULVGLFWLRQ
The rules vary depending on where the contracting parties are domiciled.
Whether parties are domiciled in a relevant Member State depends upon the
internal law of the country in question (Article 52).  A company, for example,
will be treated as being domiciled in the UK if it has its seat there.
Where at least one of the contracting parties is domiciled in the EU (or a
relevant EFTA country for the purposes of the Lugano Convention), the
parties are generally completely free to choose which court should have
jurisdiction to hear any dispute, and should do so to avoid uncertainty.  If
they agree that an EU or relevant EFTA court is to have jurisdiction, an
English court will usually regard that court as having exclusive jurisdiction
(Article 17).
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However, in proceedings concerned with the registration or validity of
patents, trade marks, or other similar registered rights, the courts of the
Member State in which the registration took place will have exclusive
jurisdiction, regardless of domicile and the parties’ choice of jurisdiction will
be overruled.  (Article 16).
If none of the parties is actually domiciled in a Member State but they
nevertheless agree that a Member State court should have jurisdiction, the
relevant court may decide whether it accepts jurisdiction.  The court of
another Member State may only accept jurisdiction if the first court declines.
(ii) 7KHSDUWLHVGRQRWFKRRVHDMXULVGLFWLRQ
Article 2 makes the general rule that persons domiciled in a Member State
shall, whatever their nationality, be sued in the courts of that state. This
means that a person can be sued in the country in which he is domiciled even
if the infringement did not occur there.  This remedy is of limited use where
the claimant wants to obtain injunctive relief in the country where the
infringement is occurring but is useful where the claimant is more concerned
with obtaining damages.
(iii) ,QWHULPRUGHUV
Even where the court of one Member State has jurisdiction over the
substance of a matter, Article 24 allows parties to apply to the court of a
different Member State for interim relief such as an injunction.
(iv) 5HFRJQLWLRQDQGHQIRUFHPHQWRIIRUHLJQMXGJPHQWV
The general rule is that a judgment obtained in one Member State must be
recognised and enforced in any other (Articles 26 and 31).  This is subject to
some exceptions, for example, where recognition or enforcement would be
contrary to public policy under the law in question  (Articles 27 and 34).
(b) Where neither Brussels nor Lugano Conventions apply
The general rule is that, in deciding whether to accept jurisdiction, the court of a
Member State must apply its own rules (Article 4). The English courts will
traditionally accept jurisdiction where the defendant has actually submitted to that
jurisdiction or where he is present in England at the time he is served with the writ.
Unless the defendant submits to the jurisdiction, the English court will only give
leave for service of the writ outside the jurisdiction where it believes it will be proper
to do so.
The European Court of Justice in the defamation case of 6KHYLOOY3UHVV$OOLDQFH
6$47gave the plaintiff the choice of bringing their action in either the place where the
damage emanated, being the place of publication, or the place where the resulting
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damage occurred, being one of the countries of distribution, thus opening up the
possibility of forum shopping.
3.3 &RXUW-XULVGLFWLRQ
Courts have full authority with respect to residents of their country, so that proceedings can
be served on a resident of the court’s country even if they are outside the jurisdiction.  In
addition, in certain circumstances, courts have jurisdiction over non-residents who are not
physically present in the jurisdiction.  To date, the application of jurisdiction of national
courts in relation to its residents and non-residents have not been consistent.  There has not
yet been a lot of European guidance on this issue.  However, there have been cases in the US
where Courts have accepted and declined jurisdiction over non-residents.  For example, in
%HQVXVDQ5HVWDXUDQW&RUSY.LQJ48, a federal district court in New York held that a Web-
site alone is not sufficient to establish personal jurisdiction.  The defendant in that case
operated a Web-site advertising its Missouri night-club, which shared its name with the
plaintiff’s New York night-club.  The plaintiff sued for trade mark infringement based on the
Web-site advertising.  The court refused to extend jurisdiction, reasoning that, “The mere
fact that a person can gain information on the allegedly infringing product is not the
equivalent of a person advertising, promoting, selling or otherwise making an effort to target
its product in New York.”  This case can be contrasted with &RPSX6HUYHY3DWWHUVRQ a
US Court of Appeal case, where Patterson, a resident of Texas entered into an on-line
agreement with the Ohio-based CompuServe for the distribution and sale of his computer
programs.  Three years later, he complained to CompuServe, via e-mail and regular mail, of
alleged trade mark violations and unfair trade practices based on CompuServe's marketing of
a similar program.  CompuServe filed an action to preclude these claims.  The US Court of
Appeal held that Patterson's transmission of the computer files, combined with his
CompuServe subscription, the on-line contract agreement and the e-mail complaints,
demonstrated that Patterson had 'knowingly reached out' to Ohio and so he should be sued
there.  The court cautioned, however, that it did not consider the issue of whether a
CompuServe subscription alone would be sufficient for a finding of personal jurisdiction.
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$11(;
4XHVWLRQQDLUH
$VKXUVW0RUULV&ULVSVROLFLWRUV
in association with
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Survey questionnaires were sent to approximately 180 organisations across Europe with an interest in
the pharmaceutical sector.  Organisations who were mailed the questionnaire broadly broke down
into four categories - pharmacists’ associations, wholesalers and wholesalers’ associations,
manufacturers and regulators.  Many organisations however had yet to consider the implications of E-
commerce internally (indeed our requests prompted such an internal examination in a number of
cases) and as a result there are a large number of European organisations (including some of the most
significant players in the market place) who have yet to determine there attitude towards E-
commerce.
In summary, the survey results reveal that manufacturers, wholesalers and pharmacists have very
different approaches towards E-commerce. The pharmacists’ associations are strongly opposed to E-
commerce in the pharmaceutical market. They deny that E-commerce could have any advantage to
the consumer and, instead, refer to possible threats to the patient’s health this new trade channel
could involve.
On the other hand, manufacturers are largely in favour of E-commerce and expect that the on-line
sale of pharmaceutical products to consumers will be used significantly in the future. However, the
survey showed a clear uncertainty about what issues constitute constraints to E-commerce, and how
E-commerce should be regulated.
Wholesalers showed less interest in the subject. As the phone calls to companies who did not respond
to the questionnaire revealed, some wholesalers still seem to be unaware of the importance E-
commerce could have to their business. Others recognise the importance of  E-commerce in the future
though not necessarily welcoming it wholeheartedly.  They, too, are unsure about existing constraints
and the issues a regulatory framework should address.
Amongst the Regulators few common themes emerged. Unsurprisingly, Regulators views were
largely determined by their attitudes to regulation and the free-market in general, so that once that
dogmatic issue had been resolved, regulators followed a largely consistent pro-free-market or pro-
regulation line.
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There follows a list of the questions asked (set out in bold type) together with a short summary of the
answers given to each question.  The answers to each question are broken down by distribution
levels:-
1. 0DUNHW,QIRUPDWLRQ
 
1.1 :KDW GR \RX VHH DV WKH SULQFLSDO UROHV WR EH SOD\HG E\ (FRPPHUFH LQ WKH (8
SKDUPDFHXWLFDOVHFWRU"
D LQWKHQH[W\HDUV
E WKHUHDIWHU"
Manufacturers
Manufacturers saw the principal role of E-commerce during the next five years as being in
the business to business sector. They expected E-commerce increasingly to be used for
trading with wholesalers, hospitals and retail pharmacy outlets. One step further would be the
sale of non-regulated products to consumers via the Internet, and information exchange with
physicians via web based media. In the long term, manufacturers expected regulatory
revisions, allowing on-line prescribing and direct trading to consumers.
Wholesalers
Whilst some wholesalers saw little future for E-commerce, the majority expected the gradual
development of E-commerce - particularly in relation to "generic" products and marketing.
Some thought that, in the long term, E-commerce would substitute traditional commerce.
Pharmacists’ associations
Pharmacists’ associations expressed the opinion that E-commerce in the pharmaceutical sector would
not play any role in the future, or at least should not in order to protect consumers’ health.
Regulators
Regulators only went so far as to say that they thought E-commerce would play a role in future.
1.2 7RZKDWH[WHQWGR\RXXVH(FRPPHUFHDOUHDG\"%\ZKLFKPHDQVHJ,QWHUQHW(’,"
’R\RXKDYHSODQVWRXVHLW"
Manufacturers
Most of the E-commerce currently used by manufacturers is restricted to business to business trade
via EDI. The Internet is used by some manufacturers to provide physician and patient
information resources.
Wholesalers
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Only one of the wholesalers questioned used the Internet for E-commerce, though some provide
information over the web.  EDI is used, though on an experimental basis, by the majority.
Pharmacists’ associations
None of the pharmacists’ associations which responded referred to any current E-commerce use by
pharmacists. One association explained that there is a “data interchange and account”
between pharmacists and the Pharmacist’ Salary Disbursement Fund for Austria, which
settles the health insurance institutions’ account with the pharmacies.  This can be carried
out by electronic means.
Regulators
Whilst regulators do not trade, some of them use EDI for emergency pharmaceutical authorisation
and the reporting of adverse pharmaceutical reactions.
1.3 3OHDVHLGHQWLI\DQGH[SODLQDQ\H[LVWLQJDQGRUIXWXUHFRQVWUDLQWVRQWKHGHYHORSPHQW
RI  (FRPPHUFH LQ WKH (8 SKDUPDFHXWLFDO VHFWRU RWKHU WKDQ OHJDO UHJXODWLRQ  IRU
ZKLFKVHHEHORZ’RWKH\LQFOXGH
D XQUHOLDELOLW\RIHOHFWURQLFPHGLDHJFRQQHFWLRQSUREOHPVRQWKH,QWHUQHW
E WKHLQVHFXULW\RIHOHFWURQLFPHGLD
F FRVWV
G SUREOHPVZLWKHOHFWURQLFSD\PHQWV\VWHPV
H ODFNRIVWUXFWXUHRQWKH,QWHUQHWHJQRLQGH[IRUVLWHVRUFRPSDQLHVRU
I WKH‡DQRQ\PLW\·RI,QWHUQHWSDUWLFLSDQWV
Manufacturers
In general, the manufacturers did not seem to be concerned about any of these issues though some
mentioned that line speed and security could constitute constraints.
Wholesalers
Costs and technical problems were not regarded as barriers to E-commerce by most wholesalers
(though there were concerns raised at the current lack of speed of the web). All wholesalers
stated that a comprehensive and standardised security system for payments was necessary
and that any new law must cover all people who are involved in E-commerce. Finally, some
mentioned that lack of quality assurance of products might become a major problem.
Pharmacists’ associations
Rather than referring to actual constraints to E-commerce in the pharmaceutical market, the
pharmacists’ associations expressed their concern about patients’ health being threatened by
counterfeit pharmaceuticals, lack of personal advice, and abuse of the prescription system
through pharmaceutical ordering without medical advice. They also thought that lay people
could find it difficult to find relevant information on the Internet. Furthermore, they saw
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security problems and some created a scenario of a two class society consisting of people
who are able to pay electronically and receive their pharmaceuticals quickly and others who
are not.
Regulators
Regulators varied widely in their estimation as to which of the named issues constituted
constraints on the development of E-commerce. In addition to the examples given in the
questions, the lack of EDI standards was mentioned.
1.4 :KDWDUHWKHNH\GULYHUVSURPRWLQJ(FRPPHUFHLQWKH(8SKDUPDFHXWLFDOVHFWRU,V
FRPSHWLWLRQRQHRIWKHP",VUHGXFLQJFRVWVDQRWKHU"
Manufacturers
Both competition and cost reduction were seen as key drivers by most of the manufacturers. Other
key drivers which were mentioned were direct contact with consumers, personal contact with
health care providers and the creation of a network of potentially interested customers.
Wholesalers
Both competition and cost reduction were seen as key drivers.  Complexity of the information to be
conveyed to customers was mentioned by one wholesaler.
Pharmacists’ associations
The pharmacists’ associations did not see any key drivers promoting E-commerce in the
pharmaceutical sector. One association argued that E-commerce in this sector would
constitute unfair competition. On-line traders would be able to undercut pharmacies prices
since they do not have to provide costly professional advice. This would constitute an unfair
advantage, to the detriment of consumer’s health.
Regulators
Both competition and cost reduction were seen as key drivers, as well as increased speed through
avoiding use of conventional paperwork.
1.5 :KDW GR \RX VHH DV WKH SULQFLSDO DGYDQWDJHV RI XVLQJ (FRPPHUFH LQ WKH (8
SKDUPDFHXWLFDOVHFWRUJHQHUDOO\"
Manufacturers
The new “communication opportunity” provided by the Internet was regarded as one major
advantage. It was argued that more complex information could be made accessible and at a
pace suited to the audience. Other advantages mentioned were lower trading costs, better
customer support and improved competitiveness.
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Wholesalers
There was little consensus amongst wholesalers, but some mentioned costs, speed, availability of
information or security in the logistical chain.  Others did not see any advantages in E-
commerce.
Pharmacists’ associations
Pharmacists’ associations saw the only potential advantage of E-commerce in the pharmaceutical
sector as being in improvements to the distribution chain between producers/wholesalers and
wholesalers/pharmacists.
Regulators
Cost, competition (particularly in combating the threat posed by direct marketing from the US) and
flexibility were named as advantages. One regulator expressed its opinion that EDI has the
potential for enhancing both quality and productivity.
1.6 :KDW GR \RX VHH DV WKH SULQFLSDO GLVDGYDQWDJHV RI XVLQJ (FRPPHUFH LQ WKH (8
SKDUPDFHXWLFDOVHFWRUJHQHUDOO\"
Manufacturers
Some manufacturers expressed their concern that E-commerce cannot be used in a very targeted way,
and that face-to-face dialogue was missing. Others mentioned that the development of
necessary skills to implement E-commerce effectively will be time-consuming, costly and
risky.
Wholesalers
The majority of wholesalers were concerned about the dangers of an uncontrolled media and of
excessive liberalisation.  Some stated that there are easier ways for commerce to take place,
without explaining this comment.
Pharmacists’ associations
Pharmacists’ associations referred to possible health risks due to free availability of pharmaceuticals
and lack of appropriate advice. They feared an increase in medicine consumption and
consequently an augmentation of public expenses due to the hospitalisation caused by
incorrect use of medicines. They were also concerned that the network of pharmacies could
be undermined by Internet traders who concentrate on the sale of profitable pharmaceuticals.
They could push pharmacies from the market, with the consequence that less profitable
medicines would not be readily available.
Regulators
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The main concern of the regulators was consumer health. They were concerned that patients may not
obtain necessary information (or that the poorer parts of society would be deprived access to
information on the Internet), confuse products or buy low quality counterfeits when using E-
commerce. A minority were also concerned about the implementation costs and security
(particularly over prescribing over the net).
1.7 :KLFKPHGLDGR\RXSUHIHUIRU(FRPPHUFHHJ,QWHUQHW(’,DQGIRUZKDWUHDVRQV"
 
Manufacturers
Both Internet and EDI were regarded as suitable for E-commerce. However, EDI was still preferred
for business-to business commerce since manufacturers do not see any existing Internet
capable of replacing EDI.
Wholesalers
EDI was the preferred media.
Pharmacists’ associations
As a result of the concerns expressed above, Pharmacists’ associations did not prefer any media for
E-commerce.
Regulators
All regulators preferred the Internet because it is easily accessible, cheap and used widely already.
2. 5HJXODWLRQ
 
2.1 ’RHVWKH OHJLVODWLRQRI\RXUFRXQWU\DOORZ(FRPPHUFH LQSKDUPDFHXWLFDOV LQFOXGLQJ
ERWK27&SURGXFWVDQGSUHVFULSWLRQSURGXFWV"
See Appendices 1 and 3 to the main study for discussion of the relevant regulations.
2.2 ,IWKHUHLVQRRXWULJKWSURKLELWLRQRI(FRPPHUFHLQSKDUPDFHXWLFDOVGR\RXWKLQNWKDW
WKHUHDUHDQ\EDUULHUVWRWKHXVHRI(FRPPHUFHLQWKHSKDUPDFHXWLFDOVVHFWRULQ\RXU
FRXQWU\ RU LQ WKH (8 UDLVHG E\ WKH FXUUHQW UHJXODWLRQV ZKLFK DUH DSSOLFDEOH LQ WKLV
VHFWRU")RUH[DPSOH
WKHDGYHUWLVLQJRUSDFNDJLQJUHJXODWLRQV
 WKHSKDUPDFLVWVPRQRSRO\
 JHQHUDOOHJLVODWLRQVXFKDVWD[UXOHV
 SUHVFULSWLRQUHTXLUHPHQWV
Manufacturers
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The prescription requirements were regarded as the main barrier to E-commerce in pharmaceuticals.
In addition, tax rules and the pharmacists monopoly were cited.
Wholesalers
All of  the points above (save general legislation) were seen as major barriers to E-commerce by
certain wholesalers though each of them placed a different emphasis on which was key.
Prescription requirements were cited in particular.
Pharmacists’ associations
No answers given.
Regulators
Regulators named advertising/packaging regulations, the pharmacists monopoly and prescription
requirements as barriers to E-commerce.
2.3 ’R \RX WKLQN WKH FXUUHQW UHJXODWRU\ IUDPHZRUN IRU SKDUPDFHXWLFDOV LV FDSDEOH RI
GHDOLQJ DGHTXDWHO\ ZLWK LVVXHV UHODWLQJ WR WKH XVH RI (FRPPHUFH LQ WKH (8
SKDUPDFHXWLFDOVHFWRU"3OHDVHJLYHUHDVRQV
Manufacturers
Manufacturers regarded the current regulatory framework as not sufficient. According to them,
prescription and reimbursement will remain problems for some years. They hoped that
gradual harmonisation on an international level will occur.
Wholesalers
Most wholesalers thought that the current regulatory framework was not capable of dealing with E-
commerce (and this was expressed in the strongest terms).  Some felt that there was a greater
chance of success in respect of business to business sales under the current regulatory
regimes and a small minority felt no new regulation was required in this regard.
Pharmacists’ associations
Pharmacists’ Associations did not want any change in the current regulatory framework as they were
opposed to E-commerce.
Regulators
All regulators that replied were of the view that the current regime is not capable of dealing
with E-commerce.
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2.4 +RZ  GR \RX WKLQN D UHJXODWRU\ IUDPHZRUN VKRXOG DGGUHVV WKH IROORZLQJ SDUWLFXODU
LVVXHV
D HOHFWURQLF FRQWUDFWLQJ QHJRWLDWLQJ FRQFOXGLQJ DQG H[HFXWLQJ FRQWUDFWV PDGH
HOHFWURQLFDOO\EHWZHHQ
(A) PDQXIDFWXUHUVDQGZKROHVDOHUV
(B) ZKROHVDOHUVDQGUHWDLOHUV
(C) UHWDLOHUVDQGFRQVXPHUVDQG
(D) GLUHFW VDOHV WR FRQVXPHUV IURP ZKROHVDOHUV RU
PDQXIDFWXUHUV
Manufacturers
Some manufacturers stated that electronic contracting should be made possible.  Others
proposed that the normal codes of practice for non-electronic trading should apply in the
electronic world.
Wholesalers
Only (A) and (B) need to be addressed.  Any regulatory framework should also address data
protection issues.
Pharmacists’ associations
It was proposed that a regulatory framework should solve all problems related to liability of
producers and traders in case of incorrect use of medicines and despatching of counterfeit
pharmaceuticals. This should be dealt with by an international agreement that must increase
the co-operation among states to enforce the rules about liability and to combat any criminal
activity.
Regulators
Contracting between manufacturers and wholesalers as well as between wholesalers and
retailers should be addressed.  One respondent raised particular issues regarding the
replacement of the pharmacists role when dealing with consumers - they suggested providing
sufficient information regarding indications, incompatibilities and adverse pharmaceutical
reactions would provide sufficient alternative consumer protection to the current pharmacy
system.
E HOHFWURQLFSD\PHQWV\VWHPVLQFOXGLQJWKHVHWWLQJRILQWHUQDWLRQDOVWDQGDUGVDQG
VHFXULW\LVVXHVVXFKDVWKHDXWKHQWLFDWLRQRIGLJLWDOVLJQDWXUHVDQGDXWKRULVDWLRQ
RISD\PHQWVE\ILQDQFLDOLQVWLWXWLRQV
Manufacturers
Should be addressed. Some stated that electronic payment systems must be based on general
commercial systems.
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Wholesalers
Should be addressed.  Any payment system should be direct from the customer’s bank.
Pharmacists’ associations
No answers given.
Regulators
Only two regulators answered this question - one stating that electronic payment systems do
not need to be addressed by a regulatory framework, and the other saying that EU wide
regulation was required.
F HOHFWURQLF VDOH RI SUHVFULSWLRQRQO\ RU UHVWULFWHG SKDUPDFHXWLFDO SURGXFWV
LQFOXGLQJ WKH JLYLQJ RI SURGXFW DGYLFH RQOLQH DQG YHULILFDWLRQ RI EX\HUV¶
LGHQWLW\
Manufacturers
Should be addressed or be subject to existing codes of conduct.
Wholesalers
Should not be addressed.
Pharmacists’ associations
No answers given.
Regulators
Only two regulators answered this question - one stating that this area should not be
addressed, whilst the other felt that EU wide regulation was required and an IT
network of pharmacists and physicians should be set up.
G HOHFWURQLF DGYHUWLVLQJ DQG FRPPHUFLDO FRPPXQLFDWLRQV LQFOXGLQJ LVVXHV
UHJDUGLQJ FRQWHQW DQG WUDGH SUDFWLFHV DQG WKH SURYLVLRQ RI RQOLQH GLDJQRVHV
DQGDGYLFH
Manufacturers
Should be subject to existing codes of conduct or be covered by country of origin.
Wholesalers
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The majority of wholesalers felt that this should not be addressed but rather be subject to
self regulation within the industry only.  A minority felt that it should be subject to some
form of prior screening process by a regulatory body.
Pharmacists’ associations
No answers given.
Regulators
Regulators expressed different views as to whether the provision of medicinal information
and advertising should be regulated. Some denied any regulation was required (and this was
the majority view in relation to non-prescription pharmaceuticals), others found it worth
considering.  One regulator in particular argued effectively for more information being made
available to the public about prescription pharmaceuticals - so long as the information was
“objective”.
H SULYDF\LQFOXGLQJWKHSURFHVVLQJDQGXVHRISHUVRQDOGDWD
Manufacturers
Should be guaranteed as much as possible.
Wholesalers
Should be addressed.
Pharmacists’ associations
No answers given.
Regulators
Only two regulators answered this question - both followed a well developed theme
in their survey replies with one arguing for no more regulation, the other for an EU
wide approach.
I OLDELOLW\ WKH RQOLQH SURYLVLRQ RI VHUYLFHV LQYROYHV D FKDLQ RI FRPPXQLFDWLRQ
&RQWHQW FDQ DOVR EH DFFHVVHG DQ\ZKHUH DQG PD\ WKHUHIRUH EUHDFK YDULRXV
QDWLRQDO ODZV7KLV UDLVHV LVVXHV DV WRZKR VKRXOGEH OLDEOH WRZKRPDQG RQ
ZKDWEDVLVIRU
(A) SURGXFWV
(B) WUDGHPDUNLQIULQJHPHQW
(C) EUHDFKRIVXSSO\FRQWUDFWV
(D) EUHDFKRIVWDWXWRU\GXWLHV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(E) FULPLQDODFWLYLWLHVRU
(F) QHJOLJHQWDFWV
Manufacturers
It was proposed that the liability should be governed by the law of the relevant plaintiff’s
country.
Wholesalers
Regarding product liability, it was proposed that there is no difference between E-commerce
and other forms of commerce.  Liability for breach of supply contracts should be covered by
the contractual provisions; breach of regulations or criminal law by the relevant statutory
provisions.
Pharmacists’ associations
No answers given.
Regulators
An EU wide approach is required particularly in relation to liability for criminal activity and
negligent acts.
J DSSOLFDEOHODZHJZKLFKFRXQWU\¶VODZVKRXOGJRYHUQWKHFRQWUDFWGHWHUPLQH
SURGXFWOLDELOLW\DQGUHJXODWHWKHFRQWHQWRIZHEVLWHV
Manufacturers
The answers varied widely on this question. One opinion was that the law of the country of
origin should apply. Another opinion was that the jurisdiction should be agreed by the
contracting parties. According to a third opinion the law of the plaintiff’s country should
apply.
Wholesalers
It was proposed that the law of the country in which the web site is established should apply,
alongside community wide legislation.
Pharmacists
No answers given.
Regulators
The law of the country where the seller is situated should apply (if possible EU law).
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2.5 +RZZLOOHOHFWURQLFWUDGLQJLQWKHSKDUPDFHXWLFDOVHFWRUDIIHFW
 
D SURGXFWOLFHQVLQJ
E QDWLRQDOSULFHUHLPEXUVHPHQW
F FRPSHWLWLRQE\JHQHULFFRS\SURGXFWVDQG
G SDUDOOHOLPSRUWDWLRQ
Manufacturers
Some manufacturers did not see a major effect on the first three areas. Others expected a
grey market to develop until a price reimbursement system for E-commerce in
pharmaceuticals is created. They also expected that there will be generic copy products
offered on the Internet which should be subject to medical approval. One manufacturer
mentioned that licence agreements will have to include a reference to this new distribution
channel in the territories section.
In respect to parallel importation, some manufacturers argued that it could be significantly
enhanced by E-commerce which simplifies the comparison of national prices. Others argued
that price differences will be reduced, if not become largely uniform, due to the introduction
of the Euro and that parallel imports will become a less important issue.
Wholesalers
Wholesalers did not seem to see any significant impact on product licensing though there
was a perceived need by a minority for an on-line database of information.  They saw price
reimbursement as a technical problem to be solved and it was felt that generic products and
parallel importation would be significantly enhanced if E-commerce was allowed.
Pharmacists’ associations
Pharmacists did not make a statement in respect to the first three parts of the question, but
stated that they did foresee a possible increase in parallel imports.
Regulators
Most regulators thought that national price reimbursement and parallel importation will be
affected. One regulator restated its opinion that national price reimbursement could be
affected through an IT network that connects physicians and pharmacists.  The opinions
differ regarding product licensing and competition by generic products.
2.6 :KDWSRVVLEOH HIIHFWV FRXOG(FRPPHUFHKDYH RQ FRPSHWLWLRQ HJ GR \RX WKLQN WKDW
DQ\OHYHOVFRXOGEHHOLPLQDWHGIURPWKHSKDUPDFHXWLFDOVXSSO\FKDLQ"
 
Manufacturers
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Manufacturers expected competition to become more vigorous and the market players to alter as a
result. Wholesalers could be forced by competition to deliver products direct to customers
and as a consequence pharmacists could be threatened.
Wholesalers
Most wholesalers thought that competition will be increased for them and that the role of pharmacies
will be seriously threatened.  A minority denied any possible effects.
Pharmacists’ associations
Most pharmacists’ associations did not see any chance of success for E-commerce in the
pharmaceutical sector. One association expressed its concern that E-commerce could have a
negative effect on pharmacists’ profit margins.
Regulators
 
Regulators thought that E-commerce will have an important economic effect on the pharmaceutical
industry though it could be restricted to OTC products. This could reduce the pharmacist’s
role in distribution to consumers.
 
3. *HQHUDO
Manufacturers
One manufacturer commented that the restrictions on E-commerce in Europe will slow down
the adoption of this new facility, but the cost advantages for the patient and the payer will
ensure its eventual dominance as the primary means of pharmaceutical delivery at all levels
of the market.
Wholesalers
Some of the wholesalers stated that they were not in favour of E-commerce for
pharmaceuticals at a consumer level because they thought that pharmacies were an
indispensable filter in the pharmaceutical market.  One wholesaler's association went so far to
say that they were not willing to accept E-commerce in the pharmaceutical sector at all.
Equally though, some associations appreciated that E-commerce was of great interest to the
public.
Pharmacists’ associations
Pharmacists’ associations emphasised the important role pharmacists play in the pharmaceutical
market.  They regarded sales over the Internet as a threat to consumer health.
Regulators
No further comments given.
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